sotalol has been researched along with Arrhythmias, Cardiac in 267 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The effectiveness of 2 doses of sotalol for complex ventricular arrhythmias has been compared with placebo in a 6-week, multicenter study (parallel, double-blind design) in 102 patients." | 10.16 | Effectiveness of sotalol for therapy of complex ventricular arrhythmias and comparisons with placebo and class I antiarrhythmic drugs. ( Anderson, JL, 1990) |
| "To determine the spontaneous variability of ventricular arrhythmias (VA) and evaluate anti-arrhythmic efficacy of mexiletine, sotalol, and a mexiletine-sotalol combination in German shepherd dogs (GSD) with inherited arrhythmias." | 9.14 | Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German shepherd dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study. ( Gelzer, AR; Hemsley, SA; Kraus, MS; Moïse, NS; Rishniw, M, 2010) |
| "Participants receiving sotalol or dofetilide for atrial or ventricular arrhythmias were randomized to receive magnesium l-lactate (504 mg elemental magnesium daily, Niche Pharmaceuticals, Roanoke, TX) or placebo for 48 hours." | 9.12 | An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. ( Coleman, CI; Guertin, D; Henyan, NN; Kluger, J; McBride, BF; Min, B; Silver, BB; White, CM, 2006) |
| " We investigated the effects of pretreatment with oral d,l-sotalol on rate-dependent changes in atrial monophasic action potential (MAP) duration after cardioversion of chronic AF with reference to the efficacy in preventing the arrhythmia recurrence." | 9.11 | Sotalol reverses remodeled action potential in patients with chronic atrial fibrillation but does not prevent arrhythmia recurrence. ( Ito, A; Kodama, I; Osaka, T; Yamazaki, M; Yokoyama, E, 2004) |
| "This study compared the efficacy and safety of sotalol and quinidine for conversion and prevention of recurrent atrial fibrillation." | 9.08 | Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. ( Baedeker, F; Hohnloser, SH; van de Loo, A, 1995) |
| "To evaluate the effects of sotalol in patients with nonsustained ventricular tachyarrhythmia (NSVT)." | 9.08 | [Brazilian multicenter study of sotalol effectiveness in ventricular arrhythmias]. ( Atie, J; Darwich, R; de Paola, AA; Gizzi, JC; Lorga, AM; Maia, IG; Perez, AK; Rassi, A; Sobral, D, 1996) |
| "We performed a randomized, double-blind, placebo-controled, parallel-group comparison study of the efficacy and safety of sotalol in the prophylaxis of paroxysmal supraventricular tachyarrhythmias (PSVTs) (including paroxysmal atrial fibrillation and paroxysmal reentrant SVTs)." | 9.08 | Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. ( Anderson, K; Joseph, SP; Joy, M; Wanless, RS, 1997) |
| "To compare the efficacy and safety of a single dose of ibutilide, a new class III antiarrhythmic drug, with that of DL-sotalol in terminating chronic atrial fibrillation or flutter in haemodynamically stable patients." | 9.08 | Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. ( Golitsyn, SR; Harry, JD; Perry, KT; Ruda, MY; Stangl, K; Steinbeck, G; Touboul, P; Van Wijk, LV; Vos, MA; Wellens, HJ, 1998) |
| "Two trial designs have been used in evaluating sotalol in patients with sustained tachyarrhythmias: open-label dose escalation and randomized comparison with reference agents." | 9.07 | Usefulness of sotalol for life-threatening ventricular arrhythmias. ( Roden, DM, 1993) |
| "The effect of sotalol on exercise tolerance and incidence of arrhythmias was studied in 30 patients with hypertrophic cardiomyopathy (HCM)." | 9.07 | Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy. ( Poloński, L; Schneeweiss, A; Tendera, M; Wodniecki, J; Wycisk, A, 1993) |
| " QTc dispersion was measured in 67 patients post myocardial infarction randomized to treatment with either sotalol or placebo." | 9.07 | Reduction in QT dispersion by sotalol following myocardial infarction. ( Campbell, RW; Day, CP; Matthews, J; McComb, JM, 1991) |
| "This open, parallel-group study compares quinidine and sotalol treatment for maintenance of sinus rhythm after direct current conversion of patients with chronic atrial fibrillation." | 9.06 | Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. ( Edvardsson, N; Juul-Möller, S; Rehnqvist-Ahlberg, N, 1990) |
| "In order to dissociate the Class III effects of sotalol on QT interval and arrhythmias from those of chronic beta-receptor blockade, we compared the effects of sotalol 160 mg b." | 9.06 | A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction. ( Alexopoulos, D; Cobbe, PC; Cobbe, SM; Johnston, J; McCaie, CP; Winner, SJ, 1988) |
| "251 untreated patients with mild to moderate hypertension were included in a multicenter study aimed 1) to detect arrhythmias (24-H Holter recording) and 2) to assess the efficacy of sotalol on blood pressure and possible arrhythmias." | 9.06 | [Cardiac arrhythmia in moderate arterial hypertension. Epidemiologic survey of 251 cases. Effect of sotalol]. ( Clémenty, J; Safar, M; Vrancea, F, 1989) |
| " Its relative efficacy towards suppressing chronic ventricular arrhythmia was tested by comparison with propranolol." | 9.06 | Randomized double blind trial comparing sotalol and propranolol in chronic ventricular arrhythmia. ( Grace, M; Klinke, WP; Kubac, G, 1988) |
| "Key safety parameters of sotalol were examined in 1,288 patients entered into recent controlled trials of ventricular (85% of patients) or supraventricular arrhythmias (15%)." | 8.78 | Clinical safety profile of sotalol in patients with arrhythmias. ( Soyka, LF; Spangenberg, RB; Wirtz, C, 1990) |
| "Sotalol and flecainide are used as second line agents in children for the treatment of supraventricular arrhythmias (SA) refractory to anti-beta adrenergic antiarrhythmics or digoxin." | 8.02 | "Second line medications" for supraventricular arrhythmias in children: In-hospital efficacy and adverse events during treatment initiation of sotalol and flecainide. ( Kahr, PC; Kim, JJ; Miyake, CY; Moffett, BS; Valdes, SO, 2021) |
| "To determine the effect of sotalol on echocardiographic indices of ventricular systolic function in dogs with ventricular arrhythmias." | 7.88 | Acute echocardiographic effects of sotalol on ventricular systolic function in dogs with ventricular arrhythmias. ( Bélanger, C; Gunther-Harrington, CT; Kaplan, JL; Mueller, MS; Nishimura, S; Oldach, MS; Stern, JA; Visser, LC, 2018) |
| " In group E, d,l-sotalol-induced prolongation of QTc and the rate and the severity of arrhythmias were significantly higher, while the dose of sotalol to initiate arrhythmias was significantly lower than those in groups C or E + P, respectively (P < ." | 7.78 | Concurrent supplement of estradiol and progesterone reduces the cardiac sensitivity to D,L-sotalol-induced arrhythmias in ovariectomized rabbits. ( Cheng, J; Li, H; Ma, X; Su, D, 2012) |
| "Cicletanine treatment significantly decreased the incidence of ventricular arrhythmias, increased cardiac cGMP and nitric oxide content and reduced cardiac cAMP level." | 7.78 | Beneficial cardiac effects of cicletanine in conscious rabbits with metabolic syndrome. ( Drimba, L; Hegedüs, C; Németh, J; Peitl, B; Sári, R; Szilvássy, Z; Yin, D, 2012) |
| "There is limited experience on sotalol use in the management of childhood arrhythmias." | 7.71 | Sotalol in treatment of pediatric cardiac arrhythmias. ( Ayabakan, C; Celiker, A; Ozer, S; Ozme, S, 2001) |
| "We sought to determine the yield of in-hospital monitoring for detection of significant arrhythmia complications in patients starting sotalol therapy for atrial arrhythmias and to identify factors that might predict safe outpatient initiation." | 7.70 | Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. ( Chung, MK; Jaeger, FJ; Kidwell, GA; Miller, DP; Morant, VA; Niebauer, MJ; Pinski, SL; Schweikert, RA; Tchou, PJ; Trohman, RG; Wilkoff, BL, 1998) |
| " She had used sotalol 80 mg once daily for three years without any episodes of proarrhythmia or other adverse effects." | 7.70 | T wave alternans after sotalol: evidence for increased sensitivity to sotalol after conversion from atrial fibrillation to sinus rhythm. ( Tan, HL; Wilde, AA, 1998) |
| " In adrenergically stimulated anesthetized rabbits, azimilide, clofilium, dofetilide, sematilide, and d,l-sotalol caused premature ventricular contractions and nonsustained and sustained ventricular tachyarrhythmias (NSVT and SVT) at pharmacologically equivalent intravenous doses that increased QTc intervals 20% (ED20)." | 7.70 | Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. ( Al-Khalidi, H; Brooks, RR; Drexler, AP; Kostreva, DR; Maynard, AE, 2000) |
| "This study sought to assess the efficacy of oral sotalol for various arrhythmias in pediatric patients and to evaluate the incidence of proarrhythmia and systemic side effects." | 7.69 | Efficacy and proarrhythmia of oral sotalol in pediatric patients. ( Kallfelz, HC; Lehmann, C; Paul, T; Pfammatter, JP, 1995) |
| "We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs." | 7.69 | Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995) |
| "We have assessed the ability of the new amiodarone-like antiarrhythmic agent, SR 33589, to reduce the incidence of ischemia- and reperfusion-induced arrhythmias, in comparison to amiodarone, D-sotalol, and lignocaine." | 7.69 | SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. ( Bruyninckx, C; Chatelain, P; Manning, AS; Ramboux, J, 1995) |
| "The efficacy and safety of sotalol therapy for ventricular arrhythmias was evaluated in 133 patients with drug-refractory ventricular arrhythmias." | 7.69 | Long-term results of electrophysiologically guided sotalol therapy for life-threatening ventricular arrhythmias. ( Epstein, LM; Fitzpatrick, AP; Grogin, HR; Lee, RJ; Lesh, MD; Namekawa-Wong, M; Scheinman, MM; Siu, A; Wong, M, 1996) |
| "The class III antiarrhythmics azimilide dihydrochloride and dl-sotalol were evaluated for ability to suppress induction of ventricular tachyarrhythmias (VT) in anesthetized, male mongrel dogs 4-6 days after surgical infarction of the left ventricle (LV) produced by ligation/reperfusion of the left anterior descending coronary artery." | 7.69 | Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. ( Brooks, RR; Drexler, AP; Micklas, JM, 1996) |
| "We explored the central hemodynamic responses to oral sotalol during dose titration in patients with ventricular arrhythmias who underwent programmed ventricular stimulation." | 7.68 | Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease. ( Deitchman, D; Gomes, JA; Kukin, M; Pe, E; Stewart, D; Winters, SL, 1993) |
| "The safety of sotalol was evaluated in 3,257 patients treated for cardiac arrhythmias in double-blind and open-label clinical trials that support United States registration of the drug." | 7.68 | Clinical safety profile of sotalol in the treatment of arrhythmias. ( Davies, RO; Deitchman, D; MacNeil, DJ, 1993) |
| " In the current study, heart rate variability assessed by time- and frequency-domain measures was determined from Holter recordings before and during treatment with sotalol in 28 patients with chronic ventricular arrhythmias." | 7.68 | Effect of sotalol on heart rate variability assessed by Holter monitoring in patients with ventricular arrhythmias. ( Hohnloser, SH; Just, H; Klingenheben, T; Zabel, M, 1993) |
| "The electrophysiologic and antiarrhythmic effects of ibutilide, sotalol, and encainide were compared in dogs 24 h after myocardial infarction." | 7.68 | Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide. ( Brunden, MN; Buchanan, LV; Gibson, JK; Kabell, G; Turcotte, UM, 1992) |
| "The effect of (+/-)-sotalol (a beta-blocker with class III antiarrhythmic activity) against reperfusion-induced arrhythmias was studied in artificially ventilated, open-chest, Sprague-Dawley and Wistar rats." | 7.67 | Effect of sotalol against reperfusion-induced arrhythmias in Sprague-Dawley and Wistar rats. ( De Champlain, J; Lamontagne, D; Nadeau, R; Rochette, L; Vermeulen, M; Yamaguchi, N, 1989) |
| "A case of QT prolongation and ventricular tachyarrhythmia in a 57-year-old patient treated with small therapeutic doses of sotalol is reported." | 7.67 | [Ventricular tachyarrhythmia induced by low doses of sotalol: torsade de pointes or polymorphous ventricular tachycardia?]. ( Ophoff, N; Toker, Y, 1988) |
| "The efficacy and safety of an intravenous dose of 40 to 100 mg sotalol was evaluated in fourteen symptomatic patients with ventricular arrhythmias occurring during maximal exercise stress testing." | 7.66 | Efficacy of intravenous sotalol on ventricular arrhythmias occurring during maximal exercise stress testing. ( Kesteloot, H; Stroobandt, R, 1983) |
| "Sotalol was given intravenously at doses of 20 to 60 mg to 20 selected patients with various cardiac arrhythmias." | 7.65 | Effects of sotalol in twenty patients with cardiac arrhythmias. ( Brosseau, A; Dumont, G; Latour, Y; LeLorier, J, 1977) |
| "Sotalol is a beta-adrenergic blocking drug with the additional property of lengthening the cardiac action potential." | 6.67 | Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery. ( Dion, R; Evenepoel, M; Evrard, P; Goenen, M; Jacquet, L; Marenne, F; Verhelst, R, 1994) |
| "Sotalol is a unique beta-blocking drug, possessing significant class III antiarrhythmic activity." | 6.67 | Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias. ( Anastasiou-Nana, MI; Anderson, JL; Freedman, RA; Gilbert, EM; Keefe, DL; MacNeil, DJ; Miller, RH; Saksena, S; Singh, S, 1991) |
| "Sotalol was compared with amiodarone in this open randomized multicentre study of patients with ventricular tachycardia or fibrillation not associated with acute myocardial infarction refractory to or intolerant of Class I drugs." | 6.66 | Multicentre randomized trial of sotalol vs amiodarone for chronic malignant ventricular tachyarrhythmias. Amiodarone vs Sotalol Study Group. ( , 1989) |
| "Sotalol was given for extended therapy to 22 of 29 patients with frequent (greater than or equal to 30/hour) complex premature ventricular complexes (PVCs) who had participated in a short-term study of sotalol vs placebo." | 6.66 | Long-term experience with sotalol in the treatment of complex ventricular arrhythmias. ( Anastasiou-Nana, MI; Anderson, JL; Askins, JC; Gilbert, EM; Menlove, RL; Nanas, JN, 1987) |
| "Procainamide was successful in 13 (39%) patients." | 6.66 | Comparative efficacy of oral sotalol and procainamide in patients with chronic ventricular arrhythmias: a multicenter study. ( Lidell, C; Rehnqvist, N; Rønnevik, PK; Sjögren, A; Yli-Uotila, RJ, 1985) |
| "Sotalol is a non-selective beta-adrenergic blocking agent without intrinsic sympathomimetic activity." | 6.58 | The Use of Intravenous Sotalol in Cardiac Arrhythmias. ( Kovoor, P; Lakkireddy, DJ; Samanta, R; Thiagalingam, A; Turner, C, 2018) |
| "Sotalol was developed as a nonselective beta-blocker in the 1960s for the treatment of hypertension and later for cardiac risk management after myocardial infarction." | 6.39 | Sotalol: a new agent for the treatment of ventricular arrhythmias. ( Grubb, BP; Samoil, D; Temesy-Armos, PN, 1994) |
| "Sotalol is a nonselective beta-adrenoceptor antagonist which prolongs cardiac repolarisation independently of its antiadrenergic action (class III antiarrhythmic properties)." | 6.38 | Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias. ( Fitton, A; Sorkin, EM, 1993) |
| "DL-Sotalol is a unique antiarrhythmic agent combining potent beta-blocking properties with the propensity to prolong cardiac repolarization in all myocardial tissues." | 6.38 | Antiarrhythmic actions of DL-sotalol in ventricular and supraventricular arrhythmias. ( Singh, BN, 1992) |
| " The effectiveness of 2 doses of sotalol for complex ventricular arrhythmias has been compared with placebo in a 6-week, multicenter study (parallel, double-blind design) in 102 patients." | 6.16 | Effectiveness of sotalol for therapy of complex ventricular arrhythmias and comparisons with placebo and class I antiarrhythmic drugs. ( Anderson, JL, 1990) |
| "Spontaneous focal arrhythmias appeared within 8-18 min following 92 microM d-sotalol in 15 of 23 hearts." | 5.31 | Modulation of arrhythmias by isoproterenol in a rabbit heart model of d-sotalol-induced long Q-T intervals. ( Moore, EN; Spear, JF, 2000) |
| "Also, the incidence of arrhythmias was greater in the winter months October to May (P < 0." | 5.31 | Gender and seasonally related differences in myocardial recovery and susceptibility to sotalol-induced arrhythmias in isolated rabbit hearts. ( Moore, EN; Spear, JF, 2000) |
| "In the presence of sotalol, torsade de pointes reproducibly occurred in atrioventricular node-blocked hearts after lowering the potassium concentration to 1." | 5.31 | Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. ( Breithardt, G; Eckardt, L; Haverkamp, W, 2002) |
| "D-sotalol and almokalant evoked torsade de pointes (TdP) and other arrhythmics, frequently." | 5.31 | Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes. ( Farkas, A; Leprán, I; Papp, JG, 2002) |
| "Sotalol appears to be an effective and well tolerated agent for treatment of complex ventricular ectopic activity, even in the setting of compromised cardiac function." | 5.28 | Short- and long-term antiarrhythmic and hemodynamic effects of d,l-sotalol in patients with symptomatic ventricular arrhythmias. ( Hohnloser, SH; Just, H; Krause, T; Zabel, M, 1992) |
| "Sotalol was withdrawn in 11 patients because of continued inducibility of ventricular tachycardia at the time of follow-up electrophysiologic study." | 5.28 | Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmias. ( Ellis, T; Lebsack, C; Mead, RH; Ruder, MA; Smith, NA; Winkle, RA, 1989) |
| "Sotalol was especially effective in reducing high grade arrhythmias (couplets, "R on T" VPCs)." | 5.27 | Long-term sotalol therapy in patients with ventricular arrhythmias. ( Mary-Rabine, L; Soumagne, D; Stiels, B, 1986) |
| "A distinct phase of ventricular arrhythmias was evident about 10 to 30 min after ligation." | 5.27 | Prevention of ventricular fibrillation by metoprolol in a pig model of acute myocardial ischaemia: absence of a major arrhythmogenic role for cyclic AMP. ( Gihwala, D; Hamm, CW; Muller, CA; Opie, LH; Peisach, M, 1986) |
| "Sotalol is a non-selective beta-adrenergic blocking agent with class III antiarrhythmic properties." | 5.27 | The effect of sotalol on exercise-induced ventricular arrhythmias. ( Glogar, D; Petzl, DH; Probst, P; Schuster, E, 1988) |
| " Twenty-nine patients with supraventricular tachyarrhythmias were treated on 31 occasions to determine the effective therapeutic dosage and optimal method of administration." | 5.27 | Sotalol infusion in the treatment of supraventricular tachyarrhythmias. ( Harte, M; Horgan, JH; Teo, KK, 1985) |
| "Severe ventricular tachyarrhythmias occurred in five of the six patients, the risk was greatest up to 20 h after the ingestion of sotalol." | 5.26 | Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication. ( Elonen, E; Laakso, M; Neuvonen, PJ; Vuorenmaa, T, 1981) |
| "To determine the spontaneous variability of ventricular arrhythmias (VA) and evaluate anti-arrhythmic efficacy of mexiletine, sotalol, and a mexiletine-sotalol combination in German shepherd dogs (GSD) with inherited arrhythmias." | 5.14 | Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German shepherd dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study. ( Gelzer, AR; Hemsley, SA; Kraus, MS; Moïse, NS; Rishniw, M, 2010) |
| "Participants receiving sotalol or dofetilide for atrial or ventricular arrhythmias were randomized to receive magnesium l-lactate (504 mg elemental magnesium daily, Niche Pharmaceuticals, Roanoke, TX) or placebo for 48 hours." | 5.12 | An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. ( Coleman, CI; Guertin, D; Henyan, NN; Kluger, J; McBride, BF; Min, B; Silver, BB; White, CM, 2006) |
| "Six patients with short QT syndrome, five of whom had received an implantable cardioverter-defibrillator (ICD) and one child, were tested with different antiarrhythmic drugs, including flecainide, sotalol, ibutilide, and hydroquinidine, to determine whether they could prolong the QT interval into the normal range and thus prevent symptoms and arrhythmia recurrences." | 5.11 | Short QT syndrome: pharmacological treatment. ( Antzelevitch, C; Bianchi, F; Borggrefe, M; Brugada, R; Calò, L; Gaita, F; Giustetto, C; Haissaguerre, M; Schimpf, R; Wolpert, C, 2004) |
| " We investigated the effects of pretreatment with oral d,l-sotalol on rate-dependent changes in atrial monophasic action potential (MAP) duration after cardioversion of chronic AF with reference to the efficacy in preventing the arrhythmia recurrence." | 5.11 | Sotalol reverses remodeled action potential in patients with chronic atrial fibrillation but does not prevent arrhythmia recurrence. ( Ito, A; Kodama, I; Osaka, T; Yamazaki, M; Yokoyama, E, 2004) |
| "Significant differences between pre- and posttreatment number of VPC, severity of arrhythmia, HR variables, or occurrence of syncope were not observed in dogs treated with atenolol or procainamide." | 5.10 | Comparison of the effects of four antiarrhythmic treatments for familial ventricular arrhythmias in Boxers. ( Atkins, CE; DeFrancesco, TC; Gordon, SG; Hamlin, RL; Keene, BW; Meurs, KM; Miller, MW; Moise, NS; Spier, AW; Wright, NA, 2002) |
| "This study compared the efficacy and safety of sotalol and quinidine for conversion and prevention of recurrent atrial fibrillation." | 5.08 | Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. ( Baedeker, F; Hohnloser, SH; van de Loo, A, 1995) |
| "The efficacy of sotalol in the treatment of sustained ventricular arrhythmias has been proved; however, whether its antiarrhythmic effect is due to a beta-blocking activity, a class III antiarrhythmic activity, or a combination of both is not known." | 5.08 | Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia. ( Antz, M; Cappato, R; Kuck, KH, 1995) |
| "To evaluate the effects of sotalol in patients with nonsustained ventricular tachyarrhythmia (NSVT)." | 5.08 | [Brazilian multicenter study of sotalol effectiveness in ventricular arrhythmias]. ( Atie, J; Darwich, R; de Paola, AA; Gizzi, JC; Lorga, AM; Maia, IG; Perez, AK; Rassi, A; Sobral, D, 1996) |
| "We performed a randomized, double-blind, placebo-controled, parallel-group comparison study of the efficacy and safety of sotalol in the prophylaxis of paroxysmal supraventricular tachyarrhythmias (PSVTs) (including paroxysmal atrial fibrillation and paroxysmal reentrant SVTs)." | 5.08 | Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. ( Anderson, K; Joseph, SP; Joy, M; Wanless, RS, 1997) |
| "The Survival With ORal D-sotalol (SWORD) trial tested the hypothesis that the prophylactic administration of oral d-sotalol would reduce total mortality in patients surviving myocardial infarction (MI) with a left ventricular ejection fraction (LVEF) of < or = 40%." | 5.08 | Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? ( Camm, AJ; Cooper, W; Friedman, PL; MacNeil, DJ; Moulton, KM; Pitt, B; Pratt, CM; Schwartz, PJ; Veltri, EP; Waldo, AL, 1998) |
| "To compare the efficacy and safety of a single dose of ibutilide, a new class III antiarrhythmic drug, with that of DL-sotalol in terminating chronic atrial fibrillation or flutter in haemodynamically stable patients." | 5.08 | Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. ( Golitsyn, SR; Harry, JD; Perry, KT; Ruda, MY; Stangl, K; Steinbeck, G; Touboul, P; Van Wijk, LV; Vos, MA; Wellens, HJ, 1998) |
| "Two trial designs have been used in evaluating sotalol in patients with sustained tachyarrhythmias: open-label dose escalation and randomized comparison with reference agents." | 5.07 | Usefulness of sotalol for life-threatening ventricular arrhythmias. ( Roden, DM, 1993) |
| "The effect of sotalol on exercise tolerance and incidence of arrhythmias was studied in 30 patients with hypertrophic cardiomyopathy (HCM)." | 5.07 | Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy. ( Poloński, L; Schneeweiss, A; Tendera, M; Wodniecki, J; Wycisk, A, 1993) |
| " QTc dispersion was measured in 67 patients post myocardial infarction randomized to treatment with either sotalol or placebo." | 5.07 | Reduction in QT dispersion by sotalol following myocardial infarction. ( Campbell, RW; Day, CP; Matthews, J; McComb, JM, 1991) |
| "This open, parallel-group study compares quinidine and sotalol treatment for maintenance of sinus rhythm after direct current conversion of patients with chronic atrial fibrillation." | 5.06 | Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. ( Edvardsson, N; Juul-Möller, S; Rehnqvist-Ahlberg, N, 1990) |
| "In order to dissociate the Class III effects of sotalol on QT interval and arrhythmias from those of chronic beta-receptor blockade, we compared the effects of sotalol 160 mg b." | 5.06 | A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction. ( Alexopoulos, D; Cobbe, PC; Cobbe, SM; Johnston, J; McCaie, CP; Winner, SJ, 1988) |
| "251 untreated patients with mild to moderate hypertension were included in a multicenter study aimed 1) to detect arrhythmias (24-H Holter recording) and 2) to assess the efficacy of sotalol on blood pressure and possible arrhythmias." | 5.06 | [Cardiac arrhythmia in moderate arterial hypertension. Epidemiologic survey of 251 cases. Effect of sotalol]. ( Clémenty, J; Safar, M; Vrancea, F, 1989) |
| " Its relative efficacy towards suppressing chronic ventricular arrhythmia was tested by comparison with propranolol." | 5.06 | Randomized double blind trial comparing sotalol and propranolol in chronic ventricular arrhythmia. ( Grace, M; Klinke, WP; Kubac, G, 1988) |
| "Recently completed Beta-Blocker Heart Attack Trial in which propranolol was administered to patients following an acute myocardial infarction resulted in a 26% decrease in total mortality and a 23% decrease in total coronary events in the propranolol-treated patients as compared to the placebo patients during the average follow-up of 25 months." | 5.05 | The Beta-Blocker Heart Attack Trial in perspective. ( Goldstein, S, 1983) |
| " Amiodarone and d-1 sotalol are representative class III drugs commonly used for drug resistant arrhythmias." | 4.79 | [Class III antiarrhythmic drugs]. ( Aiba, T; Kamakura, S, 1996) |
| "Racemic sotalol is an effective Class III antiarrhythmic agent approved by the Food and Drug Administration for the treatment of documented life-threatening ventricular arrhythmias." | 4.78 | Sotalol: a breakthrough antiarrhythmic? ( McCollam, PL; Nappi, JM, 1993) |
| "The concept of controlling cardiac arrhythmias by prolonging repolarization was first exemplified in the electrophysiologic properties of sotalol." | 4.78 | Expanding clinical role of unique class III antiarrhythmic effects of sotalol. ( Singh, BN, 1990) |
| "Key safety parameters of sotalol were examined in 1,288 patients entered into recent controlled trials of ventricular (85% of patients) or supraventricular arrhythmias (15%)." | 4.78 | Clinical safety profile of sotalol in patients with arrhythmias. ( Soyka, LF; Spangenberg, RB; Wirtz, C, 1990) |
| "IV sotalol was administered according to a prespecified initiation protocol to adult patients with refractory atrial or ventricular arrhythmias." | 4.31 | Implementation of an intravenous sotalol initiation protocol: Implications for feasibility, safety, and length of stay. ( Arora, R; Charron, J; Chicos, A; Fugaro, D; Gao, X; Gay, H; Kaplan, R; Kim, S; Knight, BP; Lin, AC; Liu, AY; Lohrmann, G; Passman, R; Patil, K; Pfenniger, A; Spoolstra, S; Verma, N, 2023) |
| "Sotalol and flecainide are used as second line agents in children for the treatment of supraventricular arrhythmias (SA) refractory to anti-beta adrenergic antiarrhythmics or digoxin." | 4.02 | "Second line medications" for supraventricular arrhythmias in children: In-hospital efficacy and adverse events during treatment initiation of sotalol and flecainide. ( Kahr, PC; Kim, JJ; Miyake, CY; Moffett, BS; Valdes, SO, 2021) |
| "Sotalol, a Vaughan-Williams Class III antiarrhythmic medication, is used to manage atrial arrhythmias." | 3.96 | Multicenter Analysis of Dosing Protocols for Sotalol Initiation. ( Biswas, M; Chung, M; Levy, A; Newton-Cheh, C; Noseworthy, PA; Rosenberg, MA; Tarakji, K; Weber, R, 2020) |
| "To determine the effect of sotalol on echocardiographic indices of ventricular systolic function in dogs with ventricular arrhythmias." | 3.88 | Acute echocardiographic effects of sotalol on ventricular systolic function in dogs with ventricular arrhythmias. ( Bélanger, C; Gunther-Harrington, CT; Kaplan, JL; Mueller, MS; Nishimura, S; Oldach, MS; Stern, JA; Visser, LC, 2018) |
| "Amiodarone has a moderate slowing effect on the VT cycle length." | 3.79 | Interactions between implantable cardioverter-defibrillators and class III agents. ( Marchlinski, FE; Movsowitz, C, 1998) |
| " In group E, d,l-sotalol-induced prolongation of QTc and the rate and the severity of arrhythmias were significantly higher, while the dose of sotalol to initiate arrhythmias was significantly lower than those in groups C or E + P, respectively (P < ." | 3.78 | Concurrent supplement of estradiol and progesterone reduces the cardiac sensitivity to D,L-sotalol-induced arrhythmias in ovariectomized rabbits. ( Cheng, J; Li, H; Ma, X; Su, D, 2012) |
| "Cicletanine treatment significantly decreased the incidence of ventricular arrhythmias, increased cardiac cGMP and nitric oxide content and reduced cardiac cAMP level." | 3.78 | Beneficial cardiac effects of cicletanine in conscious rabbits with metabolic syndrome. ( Drimba, L; Hegedüs, C; Németh, J; Peitl, B; Sári, R; Szilvássy, Z; Yin, D, 2012) |
| " Therapy with beta-adrenoblockers, amiodarone and sotalol in patients with ventricular arrhythmias was associated with improvement of parameters of SA ECG, lowering of sympathetic and augmentation of parasympathetic activity without sings of arrhrythmogenic and negative inotropic effects." | 3.72 | [Anti-arrhythmic therapy: diagnostic possibilities of signal-averaged electrocardiography and heart rate variability]. ( Morozova, OI; Pozdniakova, NV; Shevyrev, VA; Tatarchenko, IP, 2003) |
| "To analyze action of digoxin and some non-digitalis drugs (beta-blockers, verapamil, amiodarone, d,l-sotalol) and their combinations on electrical activity of atria, frequency and structure of ventricular rhythm in patients with permanent atrial fibrillation." | 3.72 | [Correction of rate and structure of ventricular rhythm in permanent atrial fibrillation: a novel pathogenetic approach]. ( Blagova, OV; Bogdanova, EA; Nedostup, AV; Platonova, AA, 2004) |
| "There is limited experience on sotalol use in the management of childhood arrhythmias." | 3.71 | Sotalol in treatment of pediatric cardiac arrhythmias. ( Ayabakan, C; Celiker, A; Ozer, S; Ozme, S, 2001) |
| "Considering the Survival With ORal D-sotalol (SWORD) study results, in which mortality was higher in patients treated by the pure class III agent D-sotalol, we tested DL- and D-sotalol (5 and 10 microM) in an in vitro model of "border zone" arrhythmias." | 3.70 | Proarrhythmic effects of DL- and D-sotalol on the "border zone" between normal and ischemic regions of isolated ventricular myocardium and antiarrhythmic effects on reperfusion. ( Ducouret, P; Flais, F; Gérard, JL; Libersa, C; Monti, F; Picard, S; Puddu, PE; Rouet, R, 1998) |
| "We sought to determine the yield of in-hospital monitoring for detection of significant arrhythmia complications in patients starting sotalol therapy for atrial arrhythmias and to identify factors that might predict safe outpatient initiation." | 3.70 | Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. ( Chung, MK; Jaeger, FJ; Kidwell, GA; Miller, DP; Morant, VA; Niebauer, MJ; Pinski, SL; Schweikert, RA; Tchou, PJ; Trohman, RG; Wilkoff, BL, 1998) |
| " She had used sotalol 80 mg once daily for three years without any episodes of proarrhythmia or other adverse effects." | 3.70 | T wave alternans after sotalol: evidence for increased sensitivity to sotalol after conversion from atrial fibrillation to sinus rhythm. ( Tan, HL; Wilde, AA, 1998) |
| " In adrenergically stimulated anesthetized rabbits, azimilide, clofilium, dofetilide, sematilide, and d,l-sotalol caused premature ventricular contractions and nonsustained and sustained ventricular tachyarrhythmias (NSVT and SVT) at pharmacologically equivalent intravenous doses that increased QTc intervals 20% (ED20)." | 3.70 | Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. ( Al-Khalidi, H; Brooks, RR; Drexler, AP; Kostreva, DR; Maynard, AE, 2000) |
| "This study sought to assess the efficacy of oral sotalol for various arrhythmias in pediatric patients and to evaluate the incidence of proarrhythmia and systemic side effects." | 3.69 | Efficacy and proarrhythmia of oral sotalol in pediatric patients. ( Kallfelz, HC; Lehmann, C; Paul, T; Pfammatter, JP, 1995) |
| " 1 and 2, atrial fibrillation was treated with either quinidine or quinidine and sotalol in combination." | 3.69 | Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports. ( Faber, TS; Hohnloser, S; Just, H; Van de Loo, A; Zehender, M, 1994) |
| "We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs." | 3.69 | Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995) |
| "We have assessed the ability of the new amiodarone-like antiarrhythmic agent, SR 33589, to reduce the incidence of ischemia- and reperfusion-induced arrhythmias, in comparison to amiodarone, D-sotalol, and lignocaine." | 3.69 | SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. ( Bruyninckx, C; Chatelain, P; Manning, AS; Ramboux, J, 1995) |
| " The time to onset of the first arrhythmia and ventricular fibrillation, induced by intravenous infusion of ouabain, was shortened in the presence of AM 92016." | 3.69 | The in-vivo cardiovascular effects of a putative class III anti-arrhythmic drug, AM 92016. ( Hagerty, MJ; Kane, KA; Wainwright, CL, 1996) |
| "The efficacy and safety of sotalol therapy for ventricular arrhythmias was evaluated in 133 patients with drug-refractory ventricular arrhythmias." | 3.69 | Long-term results of electrophysiologically guided sotalol therapy for life-threatening ventricular arrhythmias. ( Epstein, LM; Fitzpatrick, AP; Grogin, HR; Lee, RJ; Lesh, MD; Namekawa-Wong, M; Scheinman, MM; Siu, A; Wong, M, 1996) |
| "The class III antiarrhythmics azimilide dihydrochloride and dl-sotalol were evaluated for ability to suppress induction of ventricular tachyarrhythmias (VT) in anesthetized, male mongrel dogs 4-6 days after surgical infarction of the left ventricle (LV) produced by ligation/reperfusion of the left anterior descending coronary artery." | 3.69 | Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. ( Brooks, RR; Drexler, AP; Micklas, JM, 1996) |
| "The novel class III antiarrhythmic agent, azimilide, provides antifibrillatory protection in a rat model of ischemia-reperfusion arrhythmias." | 3.69 | Effects of azimilide and d,l-sotalol on the heart rate and blood pressure response to isoproterenol in anesthetized rats. ( Benn, DR; Kostreva, DR; Lowe, ER; Maynard, AE; Mittelstadt, SW, 1997) |
| "We explored the central hemodynamic responses to oral sotalol during dose titration in patients with ventricular arrhythmias who underwent programmed ventricular stimulation." | 3.68 | Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease. ( Deitchman, D; Gomes, JA; Kukin, M; Pe, E; Stewart, D; Winters, SL, 1993) |
| "The safety of sotalol was evaluated in 3,257 patients treated for cardiac arrhythmias in double-blind and open-label clinical trials that support United States registration of the drug." | 3.68 | Clinical safety profile of sotalol in the treatment of arrhythmias. ( Davies, RO; Deitchman, D; MacNeil, DJ, 1993) |
| " In the current study, heart rate variability assessed by time- and frequency-domain measures was determined from Holter recordings before and during treatment with sotalol in 28 patients with chronic ventricular arrhythmias." | 3.68 | Effect of sotalol on heart rate variability assessed by Holter monitoring in patients with ventricular arrhythmias. ( Hohnloser, SH; Just, H; Klingenheben, T; Zabel, M, 1993) |
| "The electrophysiologic and antiarrhythmic effects of ibutilide, sotalol, and encainide were compared in dogs 24 h after myocardial infarction." | 3.68 | Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide. ( Brunden, MN; Buchanan, LV; Gibson, JK; Kabell, G; Turcotte, UM, 1992) |
| "Sotalol, one of the first beta-receptor antagonists synthesized, is a promising investigational agent with remarkable efficacy for treatment of patients with ventricular and supraventricular arrhythmias." | 3.68 | Concentration/response relations for the multiple antiarrhythmic actions of sotalol. ( Barbey, JT; Funck-Brentano, C; Wang, T; Woosley, RL, 1990) |
| "The effect of (+/-)-sotalol (a beta-blocker with class III antiarrhythmic activity) against reperfusion-induced arrhythmias was studied in artificially ventilated, open-chest, Sprague-Dawley and Wistar rats." | 3.67 | Effect of sotalol against reperfusion-induced arrhythmias in Sprague-Dawley and Wistar rats. ( De Champlain, J; Lamontagne, D; Nadeau, R; Rochette, L; Vermeulen, M; Yamaguchi, N, 1989) |
| "A case of QT prolongation and ventricular tachyarrhythmia in a 57-year-old patient treated with small therapeutic doses of sotalol is reported." | 3.67 | [Ventricular tachyarrhythmia induced by low doses of sotalol: torsade de pointes or polymorphous ventricular tachycardia?]. ( Ophoff, N; Toker, Y, 1988) |
| "The efficacy and safety of an intravenous dose of 40 to 100 mg sotalol was evaluated in fourteen symptomatic patients with ventricular arrhythmias occurring during maximal exercise stress testing." | 3.66 | Efficacy of intravenous sotalol on ventricular arrhythmias occurring during maximal exercise stress testing. ( Kesteloot, H; Stroobandt, R, 1983) |
| "Sotalol was given intravenously at doses of 20 to 60 mg to 20 selected patients with various cardiac arrhythmias." | 3.65 | Effects of sotalol in twenty patients with cardiac arrhythmias. ( Brosseau, A; Dumont, G; Latour, Y; LeLorier, J, 1977) |
| " The observation of drug-associated serious adverse arrhythmic events emphasizes the need for individualized careful dose titration, particularly in patients with advanced organic heart disease." | 2.68 | Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group. ( Blanc, JJ; Cheuvart, B; Crijns, HJ; Hohnloser, SH; Meinertz, T; Rizzon, P; Stubbs, P, 1995) |
| "Acute episodes of arrhythmia are managed by bolus administration of Sotahexal [correction of Hexal]." | 2.68 | [Sotahexal pharmacodynamics in patients with ischemic heart disease]. ( Avdeĭchuk, ED; Bezprozvannyĭ, AB; Chestukhin, VV; Dorofeeva, EIu; Gorshkov, VA; Kesarev, GV; Lazutina, OM; Lyskovtsev, VV; Nesvetov, VN; Radzevich, AE, 1997) |
| "The effect of rac-sotalol on QT interval duration was studied in 10 patients after single oral administration (160 mg) and after 6-day multiple oral dosing (80 mg two or three times daily)." | 2.68 | Tolerance to the repolarization effects of rac-sotalol during long-term treatment. ( Al Bunni, M; Ferrari, M; Gusella, M; Magnolfi, G; Maiolino, P; Padrini, R; Piovan, D; Zordan, R, 1997) |
| "Sotalol is a beta-adrenergic blocking drug with the additional property of lengthening the cardiac action potential." | 2.67 | Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery. ( Dion, R; Evenepoel, M; Evrard, P; Goenen, M; Jacquet, L; Marenne, F; Verhelst, R, 1994) |
| "Sotalol is a unique beta-blocking drug, possessing significant class III antiarrhythmic activity." | 2.67 | Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias. ( Anastasiou-Nana, MI; Anderson, JL; Freedman, RA; Gilbert, EM; Keefe, DL; MacNeil, DJ; Miller, RH; Saksena, S; Singh, S, 1991) |
| "Sotalol was comparable with quinidine in reducing PVCs and VT events." | 2.67 | Sotalol versus class I and II antiarrhythmic agents. ( Hanyok, JJ; MacNeil, DJ, 1990) |
| "Sotalol was compared with amiodarone in this open randomized multicentre study of patients with ventricular tachycardia or fibrillation not associated with acute myocardial infarction refractory to or intolerant of Class I drugs." | 2.66 | Multicentre randomized trial of sotalol vs amiodarone for chronic malignant ventricular tachyarrhythmias. Amiodarone vs Sotalol Study Group. ( , 1989) |
| "Sotalol was given for extended therapy to 22 of 29 patients with frequent (greater than or equal to 30/hour) complex premature ventricular complexes (PVCs) who had participated in a short-term study of sotalol vs placebo." | 2.66 | Long-term experience with sotalol in the treatment of complex ventricular arrhythmias. ( Anastasiou-Nana, MI; Anderson, JL; Askins, JC; Gilbert, EM; Menlove, RL; Nanas, JN, 1987) |
| "Procainamide was successful in 13 (39%) patients." | 2.66 | Comparative efficacy of oral sotalol and procainamide in patients with chronic ventricular arrhythmias: a multicenter study. ( Lidell, C; Rehnqvist, N; Rønnevik, PK; Sjögren, A; Yli-Uotila, RJ, 1985) |
| "Sotalol (Sotacor) is a beta-adrenergic receptor blocking agent, which in addition possesses class III anti-arrhythmic properties." | 2.65 | The efficacy of sotalol in suppressing ventricular ectopic beats. ( Cartoon, J; Goldman, aP; Myburgh, DP; Schamroth, JM, 1979) |
| "Sotalol is a non-selective beta-adrenergic blocking agent without intrinsic sympathomimetic activity." | 2.58 | The Use of Intravenous Sotalol in Cardiac Arrhythmias. ( Kovoor, P; Lakkireddy, DJ; Samanta, R; Thiagalingam, A; Turner, C, 2018) |
| "IV sotalol has a rapid onset of action with linear pharmacokinetics." | 2.58 | Intravenous Sotalol: An Under Used Treatment Strategy. ( Kerin, NZ, 2018) |
| " Orally administered sotalol has a bioavailability of nearly 100%." | 2.53 | Sotalol. ( Kpaeyeh, JA; Wharton, JM, 2016) |
| "A new in vivo proarrhythmia model of drug-induced long QT syndrome was developed using the Microminipig, an incredibly small minipig established by Fuji Micra Inc." | 2.47 | Microminipig, a non-rodent experimental animal optimized for life science research: in vivo proarrhythmia models of drug-induced long QT syndrome: development of chronic atrioventricular block model of microminipig. ( Akie, Y; Itoh, K; Izumi, Y; Kaneko, N; Nakamura, Y; Saito, H; Sugiyama, A; Yamazaki, H, 2011) |
| "The treatment of cardiac arrhythmias has undergone a sea change with the advent of catheter ablative procedures (radiofrequency ablation) and use of implantable cardioverter defibrillator (ICD)." | 2.44 | Antiarrhythmic drugs: present and future. ( Sharma, S, 2007) |
| " Class III antiarrhythmic drugs may interact with other drugs by two major processes: pharmacodynamic and pharmacokinetic interactions." | 2.42 | Potentially significant drug interactions of class III antiarrhythmic drugs. ( DeBisschop, M; Lower, DL; Martin, LG; Yamreudeewong, W, 2003) |
| "Amiodarone is a highly efficacious antiarrhythmic agent for many cardiac arrhythmias, ranging from atrial fibrillation to malignant ventricular tachyarrhythmias, and seems to be superior to other antiarrhythmic agents." | 2.42 | Arrhythmias in the intensive care patient. ( Brandts, B; Trappe, HJ; Weismueller, P, 2003) |
| "The prevalence of arrhythmia in the population is increasing as more people survive for longer with cardiovascular disease." | 2.42 | A benefit-risk assessment of class III antiarrhythmic agents. ( Brendorp, B; Elming, H; Køber, L; Pedersen, OD; Pehrson, S; Torp-Petersen, C, 2004) |
| "Sotalol was recently shown to be effective in reducing tachyarrhythmias in patients with ICDs." | 2.41 | New advances in class III antiarrhythmic drug therapy. ( Sager, PT, 2000) |
| "Atrial fibrillation is the most common arrhythmia encountered postoperatively, although ventricular arrhythmias and conduction disturbances can also occur." | 2.41 | Cardiac surgery: postoperative arrhythmias. ( Chung, MK, 2000) |
| "D-Sotalol is a weak beta-adrenoceptor antagonist and may also be a positive inotrope." | 2.41 | D-Sotalol: death by the SWORD or deserving of further consideration for clinical use? ( Brown, L; Doggrell, SA, 2000) |
| " Sotalol requires careful patient selection due to the risk of proarrhythmia and although cardiac effects are rare with amiodarone therapy, potentially serious non-cardiac adverse effects can limit the long-term use of this agent." | 2.41 | The role of class III antiarrhythmic agents in maintaining sinus rhythm. ( Brachmann, J, 2000) |
| "Drugs can cause cardiac arrhythmias in a number of clinical situations, and many of the implicated agents are used to treat non-cardiac conditions." | 2.40 | Drug-induced cardiac arrhythmias: incidence, prevention and management. ( Doig, JC, 1997) |
| "These include catheter ablation of cardiac arrhythmias, certain surgical techniques that in selected patients offer prospects of cure, and the development of implantable ventricular and atrial cardioverter defibrillators, which allow the evaluation of drugs versus placebo against the background of the defibrillator." | 2.40 | Controlling cardiac arrhythmias: an overview with a historical perspective. ( Singh, BN, 1997) |
| "Cardiac arrhythmias frequently respond only to drugs that have as their predominant electrophysiologic effect the prolongation of repolarization and refractoriness." | 2.40 | Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs. ( Bharucha, D; Kowey, PR; Marinchak, RA; Rials, SJ, 1997) |
| "Torsades de pointes is the classic form of proarrhythmia observed during therapy with any drug that prolongs repolarization, for example, the class III agents." | 2.40 | Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. ( Hohnloser, SH, 1997) |
| "d-Sotalol has pharmacokinetic properties that resemble those of the racemate." | 2.39 | Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol. ( Advani, SV; Singh, BN, 1995) |
| "Sotalol is a beta-blocking drug devoid of membrane stabilizing properties, as well as intrinsic sympathomimetic actions, or cardioselectivity." | 2.39 | Sotalol: from "just another beta blocker" to "the prototype of class III antidysrhythmic compound". ( Claudel, JP; Touboul, P, 1995) |
| "Pharmacological therapy of cardiac arrhythmias continues to evolve, with an increasing shift from class I to class III compounds and beta-blockers." | 2.39 | Class III antiarrhythmic drugs. ( Ahmed, R; Singh, BN, 1994) |
| "Sotalol was developed as a nonselective beta-blocker in the 1960s for the treatment of hypertension and later for cardiac risk management after myocardial infarction." | 2.39 | Sotalol: a new agent for the treatment of ventricular arrhythmias. ( Grubb, BP; Samoil, D; Temesy-Armos, PN, 1994) |
| "The definition of proarrhythmia has changed since controlled clinical studies showed a dichotomy between arrhythmia suppression and mortality." | 2.39 | Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. ( Hohnloser, SH; Singh, BN, 1995) |
| "For some arrhythmias, such as atrial fibrillation, it seems likely that drug therapy will remain an important part of treatment." | 2.39 | Is there a need for new antiarrhythmic drugs? ( Roden, DM, 1996) |
| "Sotalol is a nonselective beta-adrenoceptor antagonist which prolongs cardiac repolarisation independently of its antiadrenergic action (class III antiarrhythmic properties)." | 2.38 | Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias. ( Fitton, A; Sorkin, EM, 1993) |
| "d,l-Sotalol is a racemic drug composed of equimolar amounts of d-(+)-sotalol and l-(-)-sotalol." | 2.38 | Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol. ( Funck-Brentano, C, 1993) |
| " Sotalol is highly bioavailable when administered orally in the fasting state and is mostly cleared unchanged in the urine with an apparent half-life of elimination of 15 to 17 hours." | 2.38 | Sotalol. ( Ruffy, R, 1993) |
| "Serum drug level monitoring facilitates dosage optimization of agents with a narrow therapeutic index." | 2.38 | The utility of serum drug level monitoring during therapy with class III antiarrhythmic agents. ( Follath, F, 1992) |
| "DL-Sotalol is a unique antiarrhythmic agent combining potent beta-blocking properties with the propensity to prolong cardiac repolarization in all myocardial tissues." | 2.38 | Antiarrhythmic actions of DL-sotalol in ventricular and supraventricular arrhythmias. ( Singh, BN, 1992) |
| "Torsades de pointes arrhythmia is an undesirable side-effect closely coupled to specific class-III action that may limit their future use." | 2.38 | [New anti-arrhythmia agents]. ( Honerjäger, P; Schmidt, G, 1992) |
| "Benign arrhythmias occur in the setting of structurally normal hearts and do not require therapy unless associated with debilitating symptoms." | 2.38 | Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias. ( Anderson, JL, 1990) |
| "Sotalol is a unique beta blocker in not only antagonizing sympathetic stimulation competitively, but also in exerting a potent antiarrhythmic effect by prolonging repolarization." | 2.38 | Is class III antiarrhythmic activity important? ( Singh, BN, 1990) |
| " A multicenter registry study was designed to evaluate the safety, efficacy, and dosing of IV sotalol." | 1.72 | IV Sotalol Use in Pediatric and Congenital Heart Patients: A Multicenter Registry Study. ( Asaki, SY; Avari Silva, JN; Balaji, S; Chang, PM; Fischbach, PS; Garnreiter, JM; Kirk, C; Malloy-Walton, LE; Moak, JP; Nguyen, HH; Ochoa, LA; Patel, AR; Saul, JP; Sherman, AK; Von Bergen, NH, 2022) |
| "Fetal arrhythmias are common, and they may resolve spontaneously in majority of the cases." | 1.56 | Fetal arrhythmias: diagnosis and treatment. ( Yuan, SM, 2020) |
| "Sotalol is an attractive alternative antiarrhythmic to amiodarone in this younger patient population, given the latter's toxicity profile, but it may have proarrhythmic effects." | 1.51 | Efficacy and adverse effects of sotalol in adults with congenital heart disease. ( Celermajer, DS; Cordina, RL; McGuire, MA; Moore, BM, 2019) |
| "Antazoline is a first-generation antihistamine with antiarrhythmic properties." | 1.48 | Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes. ( Dechering, DG; Eckardt, L; Ellermann, C; Fehr, M; Frommeyer, G; Kochhäuser, S; Sterneberg, M, 2018) |
| "Sotalol (220 microM) was infused in the aortic cannula, and pinacidil (20 microM) was infused through the LAD, causing a gradient in repolarization time between the two myocardial regions." | 1.35 | Dispersion of repolarization and arrhythmogenesis. ( Coronel, R; Janse, MJ; Opthof, T; Wilms-Schopman, FJ, 2009) |
| "Amiodarone and sotalol were found to have a neutral effect on survival." | 1.33 | Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators. ( Ho, AT; Pai, RG; Pai, SM; Timothy, P, 2005) |
| "Prior to polymorphic ventricular tachycardia, dispersion of APD further increased (APD70max-min: 17 +/- 3 ms; APD90max-min: 25 +/- 3 ms; p < 0." | 1.32 | Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia. ( Breithardt, G; Eckardt, L; Fabritz, L; Franz, MR; Haverkamp, W; Kirchhof, P; Milberg, P; Mönnig, G, 2003) |
| "Dose-dependent torsades de pointes has been shown to occur with dofetilide (Tikosyn) and sotalol HCl (Betapace AF); thus, detailed dosing and monitoring recommendations to minimize this risk are included in the product labeling for both drugs." | 1.32 | Evaluation of the dofetilide risk-management program. ( Allen LaPointe, NM; Califf, RM; Chen, A; DeLong, E; Hammill, B; Kramer, JM, 2003) |
| "Typical arrhythmias are torsade de pointes occurring during treatment with K(+)-channel inhibitors (e." | 1.31 | [Ion channels and arrhythmias]. ( Borchard, U; Hafner, D, 2000) |
| "Spontaneous focal arrhythmias appeared within 8-18 min following 92 microM d-sotalol in 15 of 23 hearts." | 1.31 | Modulation of arrhythmias by isoproterenol in a rabbit heart model of d-sotalol-induced long Q-T intervals. ( Moore, EN; Spear, JF, 2000) |
| "Also, the incidence of arrhythmias was greater in the winter months October to May (P < 0." | 1.31 | Gender and seasonally related differences in myocardial recovery and susceptibility to sotalol-induced arrhythmias in isolated rabbit hearts. ( Moore, EN; Spear, JF, 2000) |
| "The tachyarrhythmias were suppressed by sodium channel blocker, potassium channel blocker or magnesium." | 1.31 | Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation. ( Chang, MS; Chen, SA; Chen, YJ; Lin, CI, 2000) |
| "Torsade de pointes is a rare but potentially fatal ventricular arrhythmia associated with drug-induced delayed repolarization and prolongation of the QT interval." | 1.31 | The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. ( Cox, BF; Gintant, GA; Limberis, JT; McDermott, JS; Wegner, CD, 2001) |
| "In the presence of sotalol, torsade de pointes reproducibly occurred in atrioventricular node-blocked hearts after lowering the potassium concentration to 1." | 1.31 | Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. ( Breithardt, G; Eckardt, L; Haverkamp, W, 2002) |
| "D-sotalol and almokalant evoked torsade de pointes (TdP) and other arrhythmics, frequently." | 1.31 | Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes. ( Farkas, A; Leprán, I; Papp, JG, 2002) |
| "Ventricular proarrhythmia is avoided provided that shocks are well synchronized to R waves that are not at closely coupled intervals or preceded by long-short cycles." | 1.30 | Initial clinical experience with an implantable human atrial defibrillator. ( Camm, AJ; Ho, DS; Lau, CP; Lee, KL; Lok, NS; Murgatroyd, F; Sopher, M; Tse, HF, 1997) |
| "These arrhythmias remained unchanged in the placebo group and decreased dose dependently with sotalol." | 1.29 | Proarrhythmic effects of DPI 201-106 elicited with programmed electrical stimulation: a comparison with sotalol. ( Hof, A; Hof, RP; Novosel, D; Zierhut, W, 1993) |
| "Cardiac arrhythmias are a frequent cause of death and morbidity." | 1.29 | Iontophoresis for modulation of cardiac drug delivery in dogs. ( Labhasetwar, V; Levy, RJ; Schwendeman, SP; Underwood, T, 1995) |
| "dl-Sotalol abolished arrhythmias in ischemia and reduced the incidence of reperfusion arrhythmias to 30%." | 1.29 | Pro- and antiarrhythmic effects of d-sotalol and dl-sotalol in an isolated tissue model of ischemia and reperfusion. ( Ferrier, GR; Pasnani, JS, 1994) |
| "Occurrence rates of arrhythmias treated with drugs tested for efficacy either by suppression of inducible arrhythmias or by suppression of spontaneous ectopy were higher and equivalent for both testing methods." | 1.29 | From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. ( Lazzara, R, 1996) |
| "Sotalol appears to be an effective and well tolerated agent for treatment of complex ventricular ectopic activity, even in the setting of compromised cardiac function." | 1.28 | Short- and long-term antiarrhythmic and hemodynamic effects of d,l-sotalol in patients with symptomatic ventricular arrhythmias. ( Hohnloser, SH; Just, H; Krause, T; Zabel, M, 1992) |
| "Sotalol was withdrawn in 11 patients because of continued inducibility of ventricular tachycardia at the time of follow-up electrophysiologic study." | 1.28 | Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmias. ( Ellis, T; Lebsack, C; Mead, RH; Ruder, MA; Smith, NA; Winkle, RA, 1989) |
| "Ventricular arrhythmias play an important role in the pathophysiologic aspects of sudden cardiac death." | 1.27 | Identification of patients at high risk for sudden cardiac death. ( Bigger, JT, 1984) |
| "Association of long QT with arrhythmia does not, therefore, invalidate the principle that homogeneously prolonged APD should be anti-arrhythmic." | 1.27 | Delayed ventricular repolarization as an anti-arrhythmic principle. ( Vaughan Williams, EM, 1985) |
| "Sotalol was especially effective in reducing high grade arrhythmias (couplets, "R on T" VPCs)." | 1.27 | Long-term sotalol therapy in patients with ventricular arrhythmias. ( Mary-Rabine, L; Soumagne, D; Stiels, B, 1986) |
| "Acebutolol has both antihypertensive and antiarrhythmic effects." | 1.27 | Pharmacologic properties of acebutolol: relationship of hydrophilicity to central nervous system penetration. ( Abernethy, DR; Arendt, RM; Greenblatt, DJ, 1985) |
| "A distinct phase of ventricular arrhythmias was evident about 10 to 30 min after ligation." | 1.27 | Prevention of ventricular fibrillation by metoprolol in a pig model of acute myocardial ischaemia: absence of a major arrhythmogenic role for cyclic AMP. ( Gihwala, D; Hamm, CW; Muller, CA; Opie, LH; Peisach, M, 1986) |
| "Disopyramide was only modestly active, while flecainide and encainide had the least favorable profiles of effect in suppressing re-entry arrhythmias in this model." | 1.27 | Assessment of drug effects on spontaneous and induced ventricular arrhythmias in a 24-h canine infarction model. ( Gomoll, AW, 1987) |
| "We correlated the induction of these arrhythmias with the values of refractory period, conduction velocity, and wavelength during control and during administration of several drugs." | 1.27 | Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. ( Allessie, MA; Bonke, FI; Lammers, WJ; Rensma, PL; Schalij, MJ, 1988) |
| "Sotalol is a non-selective beta-adrenergic blocking agent with class III antiarrhythmic properties." | 1.27 | The effect of sotalol on exercise-induced ventricular arrhythmias. ( Glogar, D; Petzl, DH; Probst, P; Schuster, E, 1988) |
| "Correspondingly, ventricular arrhythmias and fibrillation were almost completely prevented by metoprolol, d-sotalol or verapamil, but increased by lidocaine." | 1.27 | Comparative investigations on the antiarrhythmic and electrophysiologic effects of class I-IV antiarrhythmic agents following acute coronary artery occlusion. ( Gülker, H; Haverkamp, W; Hindricks, G; Thale, J, 1987) |
| "Sotalol is a nonselective beta-receptor antagonist that prolongs action potential duration and refractoriness in vitro at higher concentrations than those associated with heart rate slowing." | 1.27 | Concentration-dependent pharmacologic properties of sotalol. ( Bergstrand, RH; Duff, HJ; Roden, DM; Siddoway, LA; Thompson, KA; Wang, T; Woosley, RL, 1986) |
| " Twenty-nine patients with supraventricular tachyarrhythmias were treated on 31 occasions to determine the effective therapeutic dosage and optimal method of administration." | 1.27 | Sotalol infusion in the treatment of supraventricular tachyarrhythmias. ( Harte, M; Horgan, JH; Teo, KK, 1985) |
| "Severe ventricular tachyarrhythmias occurred in five of the six patients, the risk was greatest up to 20 h after the ingestion of sotalol." | 1.26 | Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication. ( Elonen, E; Laakso, M; Neuvonen, PJ; Vuorenmaa, T, 1981) |
| "Experimental induction of pulmonary emphysema caused an increase in sensitivity of the rat to toxicity from inhalation of propellants." | 1.25 | Toxicity of aerosol propellants in the respiratory and circulatory systems. VII. Influence of pulmonary emphysema and anesthesia in the rat. ( Aviado, DM; Watanabe, T, 1975) |
| "Occlusion of the LAD artery produced arrhythmia in all of the animals, with 39% developing ventricular fibrillation (VF)." | 1.25 | Influence of the adrenal medulla on cardiac rhythm disturbances following acute coronary artery occlusions. ( Kelliher, GJ; Roberts, J; Widmer, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 71 (26.59) | 18.7374 |
| 1990's | 110 (41.20) | 18.2507 |
| 2000's | 52 (19.48) | 29.6817 |
| 2010's | 26 (9.74) | 24.3611 |
| 2020's | 8 (3.00) | 2.80 |
| Authors | Studies |
|---|---|
| Phillips, GB | 1 |
| Morgan, TK | 1 |
| Lumma, WC | 1 |
| Gomez, RP | 1 |
| Lind, JM | 1 |
| Lis, R | 1 |
| Argentieri, T | 1 |
| Sullivan, ME | 1 |
| Johnson, RE | 1 |
| Baizman, ER | 1 |
| Becker, C | 1 |
| Bohnet, EA | 1 |
| Bell, RH | 1 |
| Birsner, NC | 1 |
| Busacca, CA | 1 |
| Carabateas, PM | 1 |
| Chadwick, CC | 1 |
| Gruett, MD | 1 |
| Malloy-Walton, LE | 1 |
| Von Bergen, NH | 1 |
| Balaji, S | 1 |
| Fischbach, PS | 1 |
| Garnreiter, JM | 1 |
| Asaki, SY | 1 |
| Moak, JP | 2 |
| Ochoa, LA | 1 |
| Chang, PM | 1 |
| Nguyen, HH | 1 |
| Patel, AR | 1 |
| Kirk, C | 1 |
| Sherman, AK | 1 |
| Avari Silva, JN | 1 |
| Saul, JP | 1 |
| Liu, AY | 1 |
| Charron, J | 1 |
| Fugaro, D | 1 |
| Spoolstra, S | 1 |
| Kaplan, R | 1 |
| Lohrmann, G | 1 |
| Gao, X | 1 |
| Gay, H | 1 |
| Passman, R | 1 |
| Kim, S | 1 |
| Lin, AC | 1 |
| Chicos, A | 1 |
| Arora, R | 1 |
| Patil, K | 1 |
| Pfenniger, A | 1 |
| Knight, BP | 1 |
| Verma, N | 1 |
| Rizkallah, DH | 1 |
| Refaat, MM | 1 |
| Biswas, M | 1 |
| Levy, A | 1 |
| Weber, R | 1 |
| Tarakji, K | 1 |
| Chung, M | 1 |
| Noseworthy, PA | 1 |
| Newton-Cheh, C | 1 |
| Rosenberg, MA | 1 |
| Bai, S | 1 |
| Pei, J | 1 |
| Chen, K | 1 |
| Zhao, Y | 1 |
| Cao, H | 1 |
| Tian, L | 1 |
| Ma, Y | 1 |
| Dong, H | 1 |
| Kahr, PC | 1 |
| Moffett, BS | 1 |
| Miyake, CY | 1 |
| Kim, JJ | 1 |
| Valdes, SO | 1 |
| Kapustnick, Y | 1 |
| Lutsenko, R | 1 |
| Sуdorenko, A | 1 |
| Chatterjee, D | 1 |
| Ellermann, C | 1 |
| Sterneberg, M | 1 |
| Kochhäuser, S | 1 |
| Dechering, DG | 1 |
| Fehr, M | 1 |
| Eckardt, L | 5 |
| Frommeyer, G | 2 |
| Stock, EM | 1 |
| Zeber, JE | 1 |
| McNeal, CJ | 1 |
| Banchs, JE | 1 |
| Copeland, LA | 1 |
| Samanta, R | 1 |
| Thiagalingam, A | 1 |
| Turner, C | 1 |
| Lakkireddy, DJ | 1 |
| Kovoor, P | 1 |
| Moore, BM | 1 |
| Cordina, RL | 1 |
| McGuire, MA | 1 |
| Celermajer, DS | 1 |
| Visser, LC | 1 |
| Kaplan, JL | 1 |
| Nishimura, S | 1 |
| Gunther-Harrington, CT | 1 |
| Bélanger, C | 1 |
| Oldach, MS | 1 |
| Stern, JA | 1 |
| Mueller, MS | 1 |
| Kerin, NZ | 1 |
| Yuan, SM | 1 |
| Chen, JA | 1 |
| Ptaszek, LM | 1 |
| Celano, CM | 1 |
| Beach, SR | 1 |
| Milberg, P | 3 |
| Clauss, C | 1 |
| Schmidt, M | 1 |
| Ramtin, S | 1 |
| Kaese, S | 1 |
| Grundmann, F | 1 |
| Grotthoff, JS | 1 |
| Pott, C | 1 |
| Guérard, N | 1 |
| Jordaan, P | 1 |
| Dumotier, B | 1 |
| Brugada, J | 1 |
| Gussak, I | 1 |
| Brugada, P | 1 |
| Kermorgant, M | 1 |
| Lancien, F | 1 |
| Mimassi, N | 1 |
| Le Mével, JC | 1 |
| Gotta, V | 1 |
| Cools, F | 1 |
| van Ammel, K | 1 |
| Gallacher, DJ | 2 |
| Visser, SA | 1 |
| Sannajust, F | 1 |
| Morissette, P | 1 |
| Danhof, M | 1 |
| van der Graaf, PH | 1 |
| Robyns, T | 1 |
| Lu, HR | 1 |
| Garweg, C | 1 |
| Ector, J | 1 |
| Willems, R | 1 |
| Janssens, S | 1 |
| Nuyens, D | 1 |
| Heijman, J | 1 |
| Crijns, HJ | 2 |
| Garabelli, P | 1 |
| Stavrakis, S | 1 |
| Albert, M | 1 |
| Koomson, E | 1 |
| Parwani, P | 1 |
| Chohan, J | 1 |
| Smith, L | 1 |
| Albert, D | 1 |
| Xie, R | 1 |
| Xie, Q | 1 |
| Reynolds, D | 1 |
| Po, S | 1 |
| Kpaeyeh, JA | 1 |
| Wharton, JM | 1 |
| Coronel, R | 1 |
| Wilms-Schopman, FJ | 1 |
| Opthof, T | 1 |
| Janse, MJ | 1 |
| Gilmour, RF | 1 |
| Wu, L | 1 |
| He, L | 1 |
| Gelzer, AR | 1 |
| Kraus, MS | 1 |
| Rishniw, M | 1 |
| Hemsley, SA | 1 |
| Moïse, NS | 3 |
| Somberg, JC | 1 |
| Preston, RA | 1 |
| Ranade, V | 1 |
| Molnar, J | 1 |
| Sun, Y | 1 |
| Quan, XQ | 1 |
| Fromme, S | 1 |
| Cox, RH | 1 |
| Zhang, P | 1 |
| Zhang, L | 1 |
| Guo, D | 1 |
| Guo, J | 1 |
| Patel, C | 1 |
| Kowey, PR | 2 |
| Yan, GX | 1 |
| Cheng, J | 2 |
| Ma, X | 2 |
| Zhang, J | 1 |
| Su, D | 2 |
| Puddu, PE | 2 |
| Legrand, JC | 1 |
| Sallé, L | 1 |
| Rouet, R | 2 |
| Ducroq, J | 1 |
| Sugiyama, A | 1 |
| Nakamura, Y | 1 |
| Akie, Y | 1 |
| Saito, H | 1 |
| Izumi, Y | 1 |
| Yamazaki, H | 1 |
| Kaneko, N | 1 |
| Itoh, K | 1 |
| Li, H | 1 |
| Drimba, L | 1 |
| Hegedüs, C | 1 |
| Yin, D | 1 |
| Sári, R | 1 |
| Németh, J | 1 |
| Szilvássy, Z | 1 |
| Peitl, B | 1 |
| Meurs, KM | 1 |
| Spier, AW | 1 |
| Wright, NA | 1 |
| Atkins, CE | 1 |
| DeFrancesco, TC | 1 |
| Gordon, SG | 1 |
| Hamlin, RL | 2 |
| Keene, BW | 2 |
| Miller, MW | 1 |
| Fabritz, L | 1 |
| Kirchhof, P | 1 |
| Franz, MR | 2 |
| Mönnig, G | 1 |
| Breithardt, G | 3 |
| Haverkamp, W | 3 |
| Yamreudeewong, W | 1 |
| DeBisschop, M | 1 |
| Martin, LG | 1 |
| Lower, DL | 1 |
| Sims, JJ | 1 |
| Miller, AW | 1 |
| Ujhelyi, MR | 1 |
| Tatarchenko, IP | 1 |
| Pozdniakova, NV | 1 |
| Shevyrev, VA | 1 |
| Morozova, OI | 1 |
| Tiroke, A | 1 |
| Ganeeva, ON | 1 |
| Pratt, CM | 3 |
| Trappe, HJ | 1 |
| Brandts, B | 1 |
| Weismueller, P | 1 |
| Allen LaPointe, NM | 1 |
| Chen, A | 1 |
| Hammill, B | 1 |
| DeLong, E | 1 |
| Kramer, JM | 1 |
| Califf, RM | 1 |
| Kijtawornrat, A | 1 |
| Hamlin, DM | 1 |
| Guo, BJ | 1 |
| Li, XM | 1 |
| Lu, P | 1 |
| Qin, DG | 1 |
| Wang, L | 1 |
| Nedostup, AV | 1 |
| Blagova, OV | 1 |
| Bogdanova, EA | 1 |
| Platonova, AA | 1 |
| Gaita, F | 1 |
| Giustetto, C | 1 |
| Bianchi, F | 1 |
| Schimpf, R | 2 |
| Haissaguerre, M | 1 |
| Calò, L | 1 |
| Brugada, R | 1 |
| Antzelevitch, C | 2 |
| Borggrefe, M | 2 |
| Wolpert, C | 2 |
| Nattel, S | 1 |
| Osaka, T | 1 |
| Yamazaki, M | 1 |
| Yokoyama, E | 1 |
| Ito, A | 1 |
| Kodama, I | 1 |
| Elming, H | 1 |
| Brendorp, B | 1 |
| Pehrson, S | 1 |
| Pedersen, OD | 1 |
| Køber, L | 1 |
| Torp-Petersen, C | 1 |
| Olesin, AI | 1 |
| Shabrov, AV | 1 |
| Sinenko, VI | 1 |
| Popik, GS | 1 |
| Boldueva, SA | 1 |
| Leonova, IA | 1 |
| Poloskina, OA | 1 |
| Ho, AT | 1 |
| Pai, SM | 1 |
| Timothy, P | 1 |
| Pai, RG | 1 |
| Jost, N | 1 |
| Virág, L | 2 |
| Bitay, M | 1 |
| Takács, J | 1 |
| Lengyel, C | 1 |
| Biliczki, P | 1 |
| Nagy, Z | 1 |
| Bogáts, G | 1 |
| Lathrop, DA | 1 |
| Papp, JG | 3 |
| Varró, A | 2 |
| Fujiki, A | 1 |
| McBride, BF | 1 |
| Min, B | 1 |
| Kluger, J | 1 |
| Guertin, D | 1 |
| Henyan, NN | 1 |
| Coleman, CI | 1 |
| Silver, BB | 1 |
| White, CM | 1 |
| Mitchell, LB | 1 |
| Tegelkamp, R | 1 |
| Osada, N | 1 |
| Kaufman, ES | 1 |
| Fuchs, T | 1 |
| Groysman, R | 1 |
| Meilichov, I | 1 |
| Sharma, S | 1 |
| Patterson, E | 1 |
| Lynch, JJ | 1 |
| Lucchesi, BR | 1 |
| Simon, A | 1 |
| Lockhart, EA | 1 |
| Thomis, JA | 1 |
| Laakso, M | 4 |
| Pentikäinen, P | 1 |
| Pyörälä, K | 2 |
| Neuvonen, PJ | 3 |
| Elonen, E | 3 |
| Goldstein, S | 1 |
| Frishman, WH | 1 |
| Furberg, CD | 1 |
| Friedewald, WT | 1 |
| Myburgh, DP | 2 |
| Smith, R | 1 |
| Diamond, TH | 1 |
| Faitelson, HL | 1 |
| Sommers, DK | 1 |
| Burckhardt, D | 2 |
| Pfisterer, M | 1 |
| Hoffmann, A | 2 |
| Burkart, F | 1 |
| Emmenegger, H | 1 |
| Jost, M | 1 |
| Bolli, P | 1 |
| Buehler, FR | 1 |
| Bigger, JT | 1 |
| Pentikäinen, PJ | 2 |
| Rehnberg, S | 1 |
| Stroobandt, R | 1 |
| Kesteloot, H | 1 |
| White, RA | 1 |
| Nathan, AW | 2 |
| Hellestrand, KJ | 1 |
| Bexton, RS | 1 |
| Ward, DE | 1 |
| Spurrell, RA | 1 |
| Camm, AJ | 4 |
| Belton, P | 1 |
| Sheridan, J | 1 |
| Mulcahy, R | 1 |
| Fauchier, JP | 1 |
| Neel, C | 1 |
| Garabedian, V | 1 |
| Cosnay, P | 1 |
| Brochier, M | 1 |
| Vuorenmaa, T | 1 |
| Fitton, A | 1 |
| Sorkin, EM | 1 |
| Singer, I | 1 |
| Pfammatter, JP | 1 |
| Paul, T | 1 |
| Lehmann, C | 1 |
| Kallfelz, HC | 1 |
| Hohnloser, SH | 8 |
| van de Loo, A | 2 |
| Baedeker, F | 1 |
| Anderson, KP | 1 |
| Schloss, EJ | 1 |
| Advani, SV | 1 |
| Singh, BN | 15 |
| Pill, MW | 1 |
| McCloskey, WW | 1 |
| Meinertz, T | 1 |
| Stubbs, P | 1 |
| Blanc, JJ | 1 |
| Rizzon, P | 1 |
| Cheuvart, B | 1 |
| Wyse, KR | 1 |
| Ye, V | 1 |
| Campbell, TJ | 3 |
| Kidwell, GA | 2 |
| Gonzalez, MD | 1 |
| Novosel, D | 1 |
| Hof, A | 1 |
| Zierhut, W | 1 |
| Hof, RP | 1 |
| Epstein, AE | 1 |
| Labhasetwar, V | 1 |
| Underwood, T | 1 |
| Schwendeman, SP | 1 |
| Levy, RJ | 1 |
| Claudel, JP | 1 |
| Touboul, P | 3 |
| Funck-Brentano, C | 2 |
| Jacquet, L | 1 |
| Evenepoel, M | 1 |
| Marenne, F | 1 |
| Evrard, P | 1 |
| Verhelst, R | 1 |
| Dion, R | 1 |
| Goenen, M | 1 |
| Herzig, S | 1 |
| Beyer, T | 2 |
| Pasnani, JS | 1 |
| Ferrier, GR | 1 |
| Barlow, JB | 1 |
| Obel, IW | 1 |
| Pocock, WA | 1 |
| McKibbin, JK | 1 |
| Satoh, H | 1 |
| Porterfield, JG | 1 |
| Porterfield, LM | 1 |
| Dorian, P | 1 |
| Newman, D | 1 |
| Harris, L | 1 |
| Downar, E | 1 |
| Faber, TS | 1 |
| Zehender, M | 1 |
| Hohnloser, S | 1 |
| Just, H | 3 |
| Ahmed, R | 1 |
| Nappi, JM | 1 |
| McCollam, PL | 1 |
| Ruffy, R | 1 |
| Samoil, D | 1 |
| Grubb, BP | 1 |
| Temesy-Armos, PN | 1 |
| Winters, SL | 1 |
| Kukin, M | 1 |
| Pe, E | 1 |
| Stewart, D | 1 |
| Deitchman, D | 2 |
| Gomes, JA | 1 |
| MacNeil, DJ | 4 |
| Davies, RO | 1 |
| Roden, DM | 4 |
| Klingenheben, T | 1 |
| Zabel, M | 3 |
| Leibowitz, D | 1 |
| Tendera, M | 1 |
| Wycisk, A | 1 |
| Schneeweiss, A | 1 |
| Poloński, L | 1 |
| Wodniecki, J | 1 |
| Maia, IG | 2 |
| Seixas, TN | 1 |
| Costa, AM | 1 |
| Perez, AK | 2 |
| Alves, PA | 1 |
| Finance, O | 1 |
| Manning, A | 1 |
| Chatelain, P | 2 |
| Antz, M | 1 |
| Cappato, R | 1 |
| Kuck, KH | 1 |
| Manning, AS | 1 |
| Bruyninckx, C | 1 |
| Ramboux, J | 1 |
| Sanderson, J | 1 |
| Millar, RS | 1 |
| Lorga, AM | 1 |
| de Paola, AA | 1 |
| Rassi, A | 1 |
| Sobral, D | 1 |
| Atie, J | 1 |
| Gizzi, JC | 1 |
| Darwich, R | 1 |
| Lazzara, R | 1 |
| Hagerty, MJ | 1 |
| Wainwright, CL | 1 |
| Kane, KA | 1 |
| Aiba, T | 1 |
| Kamakura, S | 1 |
| Lee, RJ | 1 |
| Wong, M | 1 |
| Siu, A | 1 |
| Namekawa-Wong, M | 1 |
| Epstein, LM | 1 |
| Fitzpatrick, AP | 1 |
| Grogin, HR | 1 |
| Scheinman, MM | 1 |
| Lesh, MD | 1 |
| Drexler, AP | 2 |
| Micklas, JM | 1 |
| Brooks, RR | 2 |
| Hlatky, MA | 1 |
| Boothroyd, DB | 1 |
| Johnstone, IM | 1 |
| Marcus, FI | 3 |
| Hahn, E | 1 |
| Hartz, V | 1 |
| Mason, JW | 1 |
| Lau, CP | 1 |
| Tse, HF | 1 |
| Lok, NS | 1 |
| Lee, KL | 1 |
| Ho, DS | 1 |
| Sopher, M | 1 |
| Murgatroyd, F | 1 |
| Wanless, RS | 1 |
| Anderson, K | 1 |
| Joy, M | 1 |
| Joseph, SP | 1 |
| McAlister, FA | 1 |
| Teo, KK | 2 |
| Doig, JC | 1 |
| Marinchak, RA | 1 |
| Rials, SJ | 1 |
| Bharucha, D | 1 |
| Mittelstadt, SW | 1 |
| Maynard, AE | 2 |
| Benn, DR | 1 |
| Lowe, ER | 1 |
| Kostreva, DR | 2 |
| Behrens, S | 1 |
| Li, YG | 1 |
| Woosley, RL | 5 |
| Dorofeeva, EIu | 1 |
| Gorshkov, VA | 1 |
| Chestukhin, VV | 1 |
| Lyskovtsev, VV | 1 |
| Bezprozvannyĭ, AB | 1 |
| Avdeĭchuk, ED | 1 |
| Kesarev, GV | 1 |
| Lazutina, OM | 1 |
| Nesvetov, VN | 1 |
| Radzevich, AE | 1 |
| Padrini, R | 1 |
| Gusella, M | 1 |
| Al Bunni, M | 1 |
| Piovan, D | 1 |
| Zordan, R | 1 |
| Magnolfi, G | 1 |
| Maiolino, P | 1 |
| Ferrari, M | 1 |
| Picard, S | 1 |
| Monti, F | 1 |
| Ducouret, P | 1 |
| Flais, F | 1 |
| Libersa, C | 1 |
| Gérard, JL | 1 |
| Cooper, W | 1 |
| Friedman, PL | 1 |
| Moulton, KM | 1 |
| Pitt, B | 1 |
| Schwartz, PJ | 1 |
| Veltri, EP | 1 |
| Waldo, AL | 1 |
| Hsieh, MH | 1 |
| Chen, SA | 2 |
| Wen, ZC | 1 |
| Tai, CT | 1 |
| Chiang, CE | 1 |
| Ding, YA | 1 |
| Chang, MS | 2 |
| Chézalviel-Guilbert, F | 1 |
| Deplanne, V | 1 |
| Davy, JM | 1 |
| Poirier, JM | 1 |
| Xia, YZ | 1 |
| Cheymol, G | 1 |
| Weissenburger, J | 2 |
| Chung, MK | 2 |
| Schweikert, RA | 1 |
| Wilkoff, BL | 1 |
| Niebauer, MJ | 1 |
| Pinski, SL | 1 |
| Trohman, RG | 1 |
| Jaeger, FJ | 1 |
| Morant, VA | 1 |
| Miller, DP | 1 |
| Tchou, PJ | 1 |
| Movsowitz, C | 1 |
| Marchlinski, FE | 1 |
| Tan, HL | 1 |
| Wilde, AA | 1 |
| Vos, MA | 1 |
| Golitsyn, SR | 1 |
| Stangl, K | 1 |
| Ruda, MY | 1 |
| Van Wijk, LV | 1 |
| Harry, JD | 1 |
| Perry, KT | 1 |
| Steinbeck, G | 1 |
| Wellens, HJ | 1 |
| Kühlkamp, V | 1 |
| Mewis, C | 1 |
| Suchalla, R | 1 |
| Mermi, J | 1 |
| Dörnberger, V | 1 |
| Seipel, L | 1 |
| Laurenzi, F | 1 |
| Avella, A | 1 |
| Adinolfi, E | 1 |
| Dini, P | 1 |
| Bénardeau, A | 1 |
| Hondeghem, L | 1 |
| Ertel, EA | 1 |
| Al-Khalidi, H | 1 |
| Sager, PT | 1 |
| Manoach, M | 1 |
| Varon, D | 1 |
| Tribulova, N | 1 |
| Zinman, T | 1 |
| Kaplan, D | 1 |
| Khananshvili, D | 1 |
| Shainberg, A | 1 |
| Borchard, U | 1 |
| Hafner, D | 1 |
| Spear, JF | 3 |
| Moore, EN | 3 |
| Baczkó, I | 1 |
| El-Reyani, NE | 1 |
| Farkas, A | 2 |
| Iost, N | 1 |
| Leprán, I | 2 |
| Mátyus, P | 1 |
| Mérot, J | 1 |
| Probst, V | 1 |
| Debailleul, M | 1 |
| Gerlach, U | 1 |
| Le Marec, H | 1 |
| Charpentier, F | 1 |
| Peralta, AO | 1 |
| John, RM | 1 |
| Gaasch, WH | 1 |
| Taggart, PI | 1 |
| Martin, DT | 1 |
| Venditti, FJ | 1 |
| Chen, YJ | 1 |
| Lin, CI | 1 |
| Doggrell, SA | 1 |
| Brown, L | 1 |
| Brachmann, J | 2 |
| Gintant, GA | 1 |
| Limberis, JT | 1 |
| McDermott, JS | 1 |
| Wegner, CD | 1 |
| Cox, BF | 1 |
| Sarma, JS | 1 |
| Celiker, A | 1 |
| Ayabakan, C | 1 |
| Ozer, S | 1 |
| Ozme, S | 1 |
| Emori, T | 1 |
| Reiffel, JA | 1 |
| Khan, IA | 1 |
| Wit, AL | 1 |
| Hoffman, BF | 1 |
| Rosen, MR | 1 |
| Watanabe, T | 1 |
| Aviado, DM | 2 |
| Goldman, aP | 1 |
| Cartoon, J | 1 |
| Schamroth, JM | 1 |
| Tarssanen, L | 1 |
| Nag, DP | 1 |
| Chopra, SC | 1 |
| Sharma, PL | 1 |
| Latour, Y | 1 |
| Dumont, G | 1 |
| Brosseau, A | 1 |
| LeLorier, J | 1 |
| Kelliher, GJ | 3 |
| Widmer, C | 1 |
| Roberts, J | 2 |
| Follath, F | 1 |
| Honerjäger, P | 1 |
| Schmidt, G | 1 |
| Buchanan, LV | 1 |
| Kabell, G | 1 |
| Turcotte, UM | 1 |
| Brunden, MN | 1 |
| Gibson, JK | 1 |
| Campbell, R | 1 |
| Loaiza, A | 1 |
| Krause, T | 1 |
| Deedwania, PC | 1 |
| Anastasiou-Nana, MI | 2 |
| Gilbert, EM | 2 |
| Miller, RH | 1 |
| Singh, S | 1 |
| Freedman, RA | 1 |
| Keefe, DL | 1 |
| Saksena, S | 1 |
| Anderson, JL | 4 |
| Check, WA | 1 |
| Day, CP | 2 |
| McComb, JM | 2 |
| Matthews, J | 1 |
| Campbell, RW | 3 |
| Warren, R | 1 |
| Vohra, J | 1 |
| Hunt, D | 1 |
| Hamer, A | 1 |
| Keil, TU | 1 |
| Juul-Möller, S | 1 |
| Edvardsson, N | 2 |
| Rehnqvist-Ahlberg, N | 1 |
| Hanyok, JJ | 1 |
| Barbey, JT | 1 |
| Wang, T | 2 |
| Hackett, LP | 1 |
| Wojnar-Horton, RE | 1 |
| Dusci, LJ | 1 |
| Ilett, KF | 1 |
| Roberts, MJ | 1 |
| Soyka, LF | 1 |
| Wirtz, C | 1 |
| Spangenberg, RB | 1 |
| Aström, M | 1 |
| Edhag, O | 1 |
| Nyquist, O | 1 |
| Vallin, H | 1 |
| Vaughan Williams, EM | 1 |
| Harron, DW | 1 |
| Mary-Rabine, L | 1 |
| Soumagne, D | 1 |
| Stiels, B | 1 |
| Cobbe, SM | 1 |
| Alexopoulos, D | 1 |
| Winner, SJ | 1 |
| McCaie, CP | 1 |
| Cobbe, PC | 1 |
| Johnston, J | 1 |
| Nademanee, K | 2 |
| Ginestes, J | 1 |
| Dumas, M | 1 |
| d'Athis, P | 1 |
| Besancenot, JF | 1 |
| Chadoint-Noudeau, V | 1 |
| Chalopin, JM | 1 |
| Rifle, G | 1 |
| Escousse, A | 1 |
| Lamontagne, D | 1 |
| Rochette, L | 1 |
| Vermeulen, M | 1 |
| Yamaguchi, N | 1 |
| Nadeau, R | 1 |
| De Champlain, J | 1 |
| Clémenty, J | 1 |
| Safar, M | 1 |
| Vrancea, F | 1 |
| Singh, SN | 1 |
| Chen, YW | 1 |
| Cohen, A | 1 |
| Obeid, M | 1 |
| Tracy, C | 1 |
| Fletcher, RD | 1 |
| Abernethy, DR | 1 |
| Arendt, RM | 1 |
| Greenblatt, DJ | 1 |
| Kowey, P | 1 |
| Engel, T | 1 |
| Wetstein, L | 1 |
| Ruder, MA | 1 |
| Ellis, T | 1 |
| Lebsack, C | 1 |
| Mead, RH | 1 |
| Smith, NA | 1 |
| Winkle, RA | 1 |
| Schmitt, C | 1 |
| Schöls, W | 1 |
| Kübler, W | 1 |
| Fournier, C | 1 |
| Bourmayan, C | 1 |
| Cadillac, M | 1 |
| Dinanian, J | 1 |
| Blondeau, M | 1 |
| Gay, J | 1 |
| Muller, CA | 1 |
| Opie, LH | 2 |
| Hamm, CW | 1 |
| Peisach, M | 1 |
| Gihwala, D | 1 |
| Kubac, G | 1 |
| Klinke, WP | 1 |
| Grace, M | 1 |
| Blomström-Lundqvist, C | 1 |
| Dohnal, M | 1 |
| Hirsch, I | 1 |
| Lindblad, A | 1 |
| Hjalmarson, A | 1 |
| Olsson, SB | 1 |
| Huang, SK | 1 |
| Gomoll, AW | 1 |
| Ophoff, N | 1 |
| Toker, Y | 1 |
| Lloyd, EA | 1 |
| Charles, RG | 1 |
| Gordon, GD | 1 |
| Adams, CM | 1 |
| Mabin, TA | 1 |
| Commerford, PJ | 1 |
| Mahmarian, JJ | 1 |
| Verani, MS | 1 |
| Hohmann, T | 1 |
| Hill, R | 1 |
| Thornton, BC | 1 |
| Bolli, R | 1 |
| Young, JB | 1 |
| Roberts, R | 1 |
| Rensma, PL | 1 |
| Allessie, MA | 1 |
| Lammers, WJ | 1 |
| Bonke, FI | 1 |
| Schalij, MJ | 1 |
| Petzl, DH | 1 |
| Probst, P | 1 |
| Glogar, D | 1 |
| Schuster, E | 1 |
| Thale, J | 1 |
| Hindricks, G | 1 |
| Gülker, H | 1 |
| Creamer, JE | 1 |
| Shennan, A | 1 |
| Askins, JC | 1 |
| Nanas, JN | 1 |
| Menlove, RL | 1 |
| Bergstrand, RH | 1 |
| Thompson, KA | 1 |
| Siddoway, LA | 1 |
| Duff, HJ | 1 |
| Lessem, JN | 1 |
| Hamby, RA | 1 |
| Aberg, A | 1 |
| Savola, J | 1 |
| Lidell, C | 1 |
| Rehnqvist, N | 1 |
| Sjögren, A | 1 |
| Yli-Uotila, RJ | 1 |
| Rønnevik, PK | 1 |
| Harte, M | 1 |
| Horgan, JH | 1 |
| Prakash, R | 1 |
| Parmley, WW | 1 |
| Allen, HN | 1 |
| Matloff, JM | 1 |
| Lawrence, T | 1 |
| Frankl, WS | 1 |
| Khan, MI | 1 |
| Hamilton, JT | 1 |
| Manning, GW | 1 |
| Scriabine, A | 1 |
| Torchiana, ML | 1 |
| Stavorski, JM | 1 |
| Ludden, CT | 1 |
| Minsker, DH | 1 |
| Stone, CA | 1 |
| Gettes, LS | 1 |
| Belej, MA | 1 |
| Koerpel, BJ | 1 |
| Davis, LD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Evaluation Analysis and Kinetics of IV Sotalol[NCT05247320] | 167 participants (Actual) | Observational | 2022-02-04 | Completed | |||
| Determining the Effects of Two Different Anesthesia Induction Techniques on QT Distance in Cardiac Surgery Patients With Two Different QT Measurement Techniques[NCT04706104] | 60 participants (Actual) | Observational | 2020-10-10 | Completed | |||
| [NCT00000492] | Phase 3 | 0 participants | Interventional | 1977-09-30 | Completed | ||
| [NCT00000531] | Phase 3 | 0 participants | Interventional | 1992-09-30 | Completed | ||
| Congestive Heart Failure Atrial Arrhythmia Monitoring and Pacing (CHAMP)[NCT00156728] | Phase 4 | 172 participants | Interventional | 2003-10-31 | Completed | ||
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
62 reviews available for sotalol and Arrhythmias, Cardiac
| Article | Year |
|---|---|
The Use of Intravenous Sotalol in Cardiac Arrhythmias.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Humans; Injecti | 2018 |
Intravenous Sotalol: An Under Used Treatment Strategy.
Topics: Administration, Intravenous; Adrenergic beta-Antagonists; Amiodarone; Arrhythmias, Cardiac; Dose-Res | 2018 |
Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis.
Topics: Animals; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Dogs; Dose-Respo | 2015 |
Sotalol.
Topics: Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Sotalol | 2016 |
[Current application of sotalol in treatment of pediatric cardiac arrhythmia].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Humans; Sotalol | 2009 |
Microminipig, a non-rodent experimental animal optimized for life science research: in vivo proarrhythmia models of drug-induced long QT syndrome: development of chronic atrioventricular block model of microminipig.
Topics: Animals; Arrhythmias, Cardiac; Atrioventricular Block; Breeding; Disease Models, Animal; Drug Evalua | 2011 |
Potentially significant drug interactions of class III antiarrhythmic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Compounds; Drug Interactions; Hu | 2003 |
Pure class III agents for prevention of sudden cardiac death.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Comorbidity; Death, Sudden, C | 2003 |
Arrhythmias in the intensive care patient.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; | 2003 |
A benefit-risk assessment of class III antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Combined Modalit | 2004 |
[Present status in and prospects for anti-arrhythmic drug therapy: How to use type III anti-arrhythmic agents].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bepridil; Drug Therapy, Combination; Human | 2006 |
Prophylactic therapy to prevent atrial arrhythmia after cardiac surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Cardiac Surgic | 2007 |
Quinidine in short QT syndrome: an old drug for a new disease.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; | 2007 |
Antiarrhythmic drugs: present and future.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Design; Humans; Hydantoins; Imidazoli | 2007 |
Beta-adrenergic blockade for survivors of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Alprenolol; Arrhythmias, Cardiac; Clinical Trials as Topic; Coron | 1984 |
Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.
Topics: Arrhythmias, Cardiac; Humans; Sotalol; Treatment Outcome | 1993 |
Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.
Topics: Animals; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrophysiology; Hemodynamics; Humans; So | 1995 |
[Sotalol].
Topics: Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Electrocardiography; Humans; Metabolic Clear | 1995 |
Sotalol: from "just another beta blocker" to "the prototype of class III antidysrhythmic compound".
Topics: Animals; Arrhythmias, Cardiac; Dogs; Humans; Sotalol | 1995 |
Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
Topics: Action Potentials; Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhyth | 1993 |
Electrophysiologic properties of sotalol and d-sotalol. A current view.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Heart Conduction Syst | 1993 |
Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardia | 1993 |
Class III antiarrhythmic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiogra | 1994 |
Sotalol: a breakthrough antiarrhythmic?
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrophysiology; | 1993 |
Sotalol.
Topics: Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Humans; Sotalol | 1993 |
Sotalol: a new agent for the treatment of ventricular arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Humans; Sotalol; Tachycardia, Supraventricular | 1994 |
Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Heart; | 1993 |
Sotalol: a novel beta-blocker with class III anti-arrhythmic activity.
Topics: Arrhythmias, Cardiac; Heart Ventricles; Hemodynamics; Humans; Myocardial Ischemia; Sotalol; Tachycar | 1993 |
Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Forecasting; Humans; In | 1995 |
Is there a need for new antiarrhythmic drugs?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduction System; Humans; Propafeno | 1996 |
[Class III antiarrhythmic drugs].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Humans; Sotalol | 1996 |
Antiarrhythmic therapies for the prevention of sudden cardiac death.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Artery Bypass; Death, Sudden, Car | 1997 |
Drug-induced cardiac arrhythmias: incidence, prevention and management.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anti-Infective Agents; | 1997 |
Controlling cardiac arrhythmias: an overview with a historical perspective.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Tria | 1997 |
Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Compounds; Humans; Phenethylamin | 1997 |
Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduction System; Humans; Myocardia | 1997 |
Risks of initiating therapy with sotalol for treatment of atrial fibrillation.
Topics: Aged; Ambulatory Care; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flu | 1998 |
Interactions between implantable cardioverter-defibrillators and class III agents.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Defibrillators, Implantable; Dise | 1998 |
New advances in class III antiarrhythmic drug therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Humans; Hydantoins; Imi | 2000 |
Cardiac surgery: postoperative arrhythmias.
Topics: Algorithms; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Cardiac Surgic | 2000 |
D-Sotalol: death by the SWORD or deserving of further consideration for clinical use?
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Dogs; Humans; Sotal | 2000 |
The role of class III antiarrhythmic agents in maintaining sinus rhythm.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Heart Conduction Syst | 2000 |
Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Tria | 2001 |
Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Appendage; Atrial Fibrillation; Atrial | 2002 |
Electrophysiology and pharmacology of cardiac arrhythmias. IX. Cardiac electrophysiologic effects of beta adrenergic receptro stimulation and blockade. Part C.
Topics: Action Potentials; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Alprenolol; Animals; Anti- | 1975 |
The utility of serum drug level monitoring during therapy with class III antiarrhythmic agents.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Sotalol | 1992 |
Antiarrhythmic actions of DL-sotalol in ventricular and supraventricular arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Electrophysiology; Hemodynamics; Humans; Sotalol; Stereoisomerism | 1992 |
[New anti-arrhythmia agents].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardio | 1992 |
Class III drugs: their effects on arrhythmias and on the QT interval.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; | 1992 |
Suppressant effects of conventional beta blockers and sotalol on complex and repetitive ventricular premature complexes.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Heart Vent | 1990 |
Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias.
Topics: Amiodarone; Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; | 1990 |
Is class III antiarrhythmic activity important?
Topics: Animals; Arrhythmias, Cardiac; Humans; Hypothyroidism; In Vitro Techniques; Sotalol | 1990 |
Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Heart; Humans; Sotalol | 1990 |
Effectiveness of sotalol for therapy of complex ventricular arrhythmias and comparisons with placebo and class I antiarrhythmic drugs.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; Heart Ventricles; Humans; Multice | 1990 |
Expanding clinical role of unique class III antiarrhythmic effects of sotalol.
Topics: Arrhythmias, Cardiac; Electrocardiography; Humans; Sotalol | 1990 |
Clinical safety profile of sotalol in patients with arrhythmias.
Topics: Arrhythmias, Cardiac; Heart Failure; Humans; Sotalol | 1990 |
Clinical pharmacology of antiarrhythmic agents.
Topics: Adrenergic beta-Antagonists; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamid | 1985 |
Antiarrhythmic drug therapy of ventricular arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Tosylate; Disopyramide; Flecaini | 1986 |
Sotalol: a beta blocker with unique antiarrhythmic properties.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Sotalol | 1987 |
Beta-adrenergic receptor blocking drugs.
Topics: Adrenergic beta-Antagonists; Alprenolol; Angina Pectoris; Aortic Aneurysm; Aortic Valve; Arrhythmias | 1973 |
Beta adrenergic blocking drugs in the treatment of cardiac arrhythmias.
Topics: Adrenergic beta-Antagonists; Alprenolol; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atrial Fibrillatio | 1970 |
Anti-arrhythmic actions of -adrenergic receptor antagonists: review of fundamental aspects.
Topics: Action Potentials; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Arrhythmias, Card | 1972 |
47 trials available for sotalol and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German shepherd dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cross-Over Studies; Dog Diseases; Dogs; Drug | 2010 |
QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol.
Topics: Administration, Oral; Adolescent; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cross-Over St | 2010 |
Comparison of the effects of four antiarrhythmic treatments for familial ventricular arrhythmias in Boxers.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Dog Diseases; Dogs; Drug Therapy, C | 2002 |
Short QT syndrome: pharmacological treatment.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Death, Sudden, Cardiac | 2004 |
Sotalol reverses remodeled action potential in patients with chronic atrial fibrillation but does not prevent arrhythmia recurrence.
Topics: Action Potentials; Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2004 |
An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chi-Square Distribution; D | 2006 |
The Beta-Blocker Heart Attack Trial in perspective.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sud | 1983 |
Beta-adrenergic blockade for survivors of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Alprenolol; Arrhythmias, Cardiac; Clinical Trials as Topic; Coron | 1984 |
A comparison of the efficacy of sotalol and nadolol in the suppression of ventricular ectopic beats.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Humans; Middle | 1983 |
Effects of the beta-adrenoceptor-blocking agent Sotalol on ventricular arrhythmias in patients with chronic ischemic heart disease. A placebo-controlled, double-blind cross-over study.
Topics: Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Double-Blind Meth | 1983 |
Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Drug Administration Schedul | 1995 |
ESVEM tells us what we don't know.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography, Ambulatory; Electrophysiology; Hu | 1995 |
Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method | 1995 |
Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery.
Topics: Administration, Oral; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia; Cardia | 1994 |
Sotalol in patients with implanted automatic defibrillators: effects on defibrillation and comparison with amiodarone.
Topics: Administration, Oral; Amiodarone; Arrhythmias, Cardiac; Combined Modality Therapy; Defibrillators, I | 1994 |
Usefulness of sotalol for life-threatening ventricular arrhythmias.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Hu | 1993 |
Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Double-Blind Method; Exercise | 1993 |
[Antiarrhythmic drug effectiveness. Proposal for a new approach based on pharmacological hourly effects].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Autonomic Nervous System; Circadian Rhyth | 1995 |
Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, | 1995 |
Proarrhythmic complications of sotalol.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Hospitals, Teaching; Humans; Male; New South W | 1996 |
[Brazilian multicenter study of sotalol effectiveness in ventricular arrhythmias].
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Arrhythmias, Cardia | 1996 |
Long-term cost-effectiveness of alternative management strategies for patients with life-threatening ventricular arrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM) Investigators.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cost-Benefit Analysis; Electrocardiography, Ambu | 1997 |
Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; D | 1997 |
[Sotahexal pharmacodynamics in patients with ischemic heart disease].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Animals; Anti-Arrhythmia Agents; Arrhyt | 1997 |
Tolerance to the repolarization effects of rac-sotalol during long-term treatment.
Topics: Action Potentials; Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Anti- | 1997 |
Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Male; Middle Age | 1998 |
Effects of antiarrhythmic drugs on variability of ventricular rate and exercise performance in chronic atrial fibrillation complicated with ventricular arrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Chi-Square | 1998 |
Interactions between implantable cardioverter-defibrillators and class III agents.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Defibrillators, Implantable; Dise | 1998 |
Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; | 1998 |
The efficacy of sotalol in suppressing ventricular ectopic beats.
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Midd | 1979 |
Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Chronic Disease; Circadian Rhythm; | 1991 |
Reduction in QT dispersion by sotalol following myocardial infarction.
Topics: Arrhythmias, Cardiac; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; M | 1991 |
Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Death, Sudden; Dose-Response Rel | 1990 |
Sotalol versus class I and II antiarrhythmic agents.
Topics: Arrhythmias, Cardiac; Double-Blind Method; Hemodynamics; Humans; Propranolol; Quinidine; Sotalol | 1990 |
Effectiveness of sotalol for therapy of complex ventricular arrhythmias and comparisons with placebo and class I antiarrhythmic drugs.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; Heart Ventricles; Humans; Multice | 1990 |
Electrophysiological effects of intravenous sotalol in acute myocardial infarction: a double-blind placebo-controlled study.
Topics: Arrhythmias, Cardiac; Atrioventricular Node; Clinical Trials as Topic; Double-Blind Method; Electroc | 1990 |
A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Cardiac Complexes, Premature; Clinical Trials as Topic; | 1988 |
[Cardiac arrhythmia in moderate arterial hypertension. Epidemiologic survey of 251 cases. Effect of sotalol].
Topics: Adult; Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Humans; Hypertension; Male; Middle A | 1989 |
Multicentre randomized trial of sotalol vs amiodarone for chronic malignant ventricular tachyarrhythmias. Amiodarone vs Sotalol Study Group.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Blood Pressure; Electrocardiography; Electrocardiogra | 1989 |
[Intermediate-term trial treatment of arrhythmia in hypertrophic myocardiopathy with sotalol].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiomegaly; Clinical Trials as T | 1988 |
Randomized double blind trial comparing sotalol and propranolol in chronic ventricular arrhythmia.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic; Double-Bli | 1988 |
Effect of long term treatment with metoprolol and sotalol on ventricular repolarisation measured by use of transoesophageal atrial pacing.
Topics: Aged; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Clinical Trials as Topic; Computers; Double- | 1986 |
Beta-blockade by sotalol in early myocardial infarction decreases ventricular arrhythmias without increasing left ventricular volume.
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Female; Heart Ventricles; Hemodynamics; | 1988 |
The hemodynamic effects of sotalol and quinidine: analysis by use of rest and exercise gated radionuclide angiography.
Topics: Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Female; Heart; Hemodynami | 1987 |
Acute and chronic effects of sotalol and propranolol on ventricular repolarization using constant-rate pacing.
Topics: Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Clinical Trials as Topic; Electrocardiography; Fe | 1986 |
Long-term experience with sotalol in the treatment of complex ventricular arrhythmias.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Drug Administration Sche | 1987 |
Comparative efficacy of oral sotalol and procainamide in patients with chronic ventricular arrhythmias: a multicenter study.
Topics: Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic; Dose-Response Relation | 1985 |
161 other studies available for sotalol and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardia | 1992 |
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzodiazepines; Cats; Disease Models, Animal | 1993 |
IV Sotalol Use in Pediatric and Congenital Heart Patients: A Multicenter Registry Study.
Topics: Arrhythmias, Cardiac; Child; Heart Defects, Congenital; Humans; Infant; Registries; Sotalol; Tachyca | 2022 |
Implementation of an intravenous sotalol initiation protocol: Implications for feasibility, safety, and length of stay.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Feasibility Studies; Female; Humans; Leng | 2023 |
Safety and effect on length of stay of intravenous sotalol initiation for arrhythmia management.
Topics: Administration, Intravenous; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Length of Stay; S | 2023 |
Multicenter Analysis of Dosing Protocols for Sotalol Initiation.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bradycardia; Drug D | 2020 |
Assessment of Drug Proarrhythmic Potential in Electrically Paced Human Induced Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes Using Multielectrode Array.
Topics: Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Cations, Divalent; Cell Di | 2021 |
"Second line medications" for supraventricular arrhythmias in children: In-hospital efficacy and adverse events during treatment initiation of sotalol and flecainide.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Flecainide; Hospitals; Humans; Sotalol | 2021 |
COMBINED PHARMACOLOGICAL THERAPY INCLUDING SEVERAL ANTIARRHYTHMIC AGENTS FOR TREATMENT OF DIFFERENT DISORDERS OF CARDIAC RHYTHM.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Propafenone; Sotalol | 2021 |
A case of palpitation and pre-syncope.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Humans; Sotalol; Sy | 2017 |
Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Antazoline; Anti-Bacterial Agents; Arrhythm | 2018 |
Psychotropic Pharmacotherapy Associated With QT Prolongation Among Veterans With Posttraumatic Stress Disorder.
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Arrhythmias, Cardiac; Buspirone; Female; Humans; Male | 2018 |
Efficacy and adverse effects of sotalol in adults with congenital heart disease.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Australia; Child; Drug-Relate | 2019 |
Acute echocardiographic effects of sotalol on ventricular systolic function in dogs with ventricular arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dog Diseases; Dogs; Echocardiography; Female; | 2018 |
Has intravenous sotalol come of age as an alternative treatment for arrhythmias in the young heart?
Topics: Arrhythmias, Cardiac; Child; Heart; Heart Defects, Congenital; Humans; Sotalol | 2018 |
Fetal arrhythmias: diagnosis and treatment.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Digoxin; Female; Humans; Hydrops Fetalis; Pregnancy; S | 2020 |
Case 9-2019: A 62-Year-Old Man with Atrial Fibrillation, Depression, and Worsening Anxiety.
Topics: Adrenergic beta-Antagonists; Alcohol Drinking; Antidepressive Agents; Anxiety Disorders; Aripiprazol | 2019 |
Electrophysiological profile of vernakalant in an experimental whole-heart model: the absence of proarrhythmia despite significant effect on myocardial repolarization.
Topics: Acetanilides; Action Potentials; Animals; Anisoles; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; El | 2014 |
Analysis of unipolar electrograms in rabbit heart demonstrated the key role of ventricular apicobasal dispersion in arrhythmogenicity.
Topics: Animals; Anti-Arrhythmia Agents; Antioxidants; Arrhythmias, Cardiac; Chromans; Electrophysiologic Te | 2014 |
Short QT syndrome: a predictable story.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Electrocardiography; Female; H | 2014 |
Central actions of serotonin and fluoxetine on the QT interval of the electrocardiogram in trout.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Drug Administration Routes; Electrocardi | 2015 |
Evaluation of Index of Cardio-Electrophysiological Balance (iCEB) as a New Biomarker for the Identification of Patients at Increased Arrhythmic Risk.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biomarkers, Pharmacological; Brugada Syndrome; | 2016 |
T-wave Right Slope Provides a New Angle in the Prediction of Drug-Induced Ventricular Arrhythmias : Editorial to: "Electrocardiographic Predictors of Torsadogenic Risk During Dofetilide or Sotalol Initiation: Utility of a Novel T Wave Analysis Program" by
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Heart Conduction System; Humans; | 2015 |
Comparison of QT Interval Readings in Normal Sinus Rhythm Between a Smartphone Heart Monitor and a 12-Lead ECG for Healthy Volunteers and Inpatients Receiving Sotalol or Dofetilide.
Topics: Action Potentials; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Case-Control Studies; Electro | 2016 |
Dispersion of repolarization and arrhythmogenesis.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Electrocardiography; Electrophysiologic Techniques | 2009 |
Restitution, heterogeneity and unidirectional conduction block: New roles for old players.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Electrocardiography; Electrophysiologic Techniques | 2009 |
A novel mutation in the KCNH2 gene associated with short QT syndrome.
Topics: Adolescent; Adult; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Electrocardiography | 2011 |
Diverse modulating effects of estradiol and progesterone on the monophasic action potential duration in Langendorff-perfused female rabbit hearts.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Dose-Response Relatio | 2012 |
I(Kr) vs. I(Ks) blockade and arrhythmogenicity in normoxic rabbit Purkinje fibers: does it really make a difference?
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chromans; Delayed Rectifie | 2011 |
Concurrent supplement of estradiol and progesterone reduces the cardiac sensitivity to D,L-sotalol-induced arrhythmias in ovariectomized rabbits.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Drug Therap | 2012 |
Beneficial cardiac effects of cicletanine in conscious rabbits with metabolic syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Cardiac Pa | 2012 |
Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; Elect | 2003 |
Electrical heterogeneity and arrhythmogenesis: importance of conduction velocity dispersion.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Vessels; Disease Models, Animal; Ele | 2003 |
[Anti-arrhythmic therapy: diagnostic possibilities of signal-averaged electrocardiography and heart rate variability].
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Data I | 2003 |
[Effect of drug therapy on frequency of adequate discharges of implanted cardioverter defibrillator].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Chann | 2003 |
Evaluation of the dofetilide risk-management program.
Topics: Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Electroc | 2003 |
QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cisapride; Consciousness; Electro | 2003 |
[Sotalol in treatment of pediatric severe (refractory) cardiac arrhythmias].
Topics: Adolescent; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Child, Preschool; Female; Follow-Up | 2003 |
[Correction of rate and structure of ventricular rhythm in permanent atrial fibrillation: a novel pathogenetic approach].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Digoxin; Electrocardi | 2004 |
Is atrial remodeling a viable target for prevention of atrial fibrillation recurrence?
Topics: Action Potentials; Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2004 |
[Possibility of differentiated treatment of ventricular heart rate disturbances based on mechanism of their development].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Sotalol; Ventricular Dysfunction | 2005 |
Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Combined Moda | 2005 |
Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle.
Topics: Action Potentials; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart; Heart Ventric | 2005 |
Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Do | 2007 |
Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia | 2008 |
Antiarrhythmic and antifibrillatory actions of the beta adrenergic receptor antagonist, dl-sotalol.
Topics: Animals; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Electric Stimulation; Electrocardiograp | 1984 |
Sotalol.
Topics: Arrhythmias, Cardiac; Humans; Sotalol | 1980 |
Sotalol and the Q-Tc interval.
Topics: Arrhythmias, Cardiac; Electrocardiography; Humans; Hypertension; Sotalol | 1981 |
Sotalol and the Q-Tc interval.
Topics: Arrhythmias, Cardiac; Drug Labeling; Electrocardiography; Humans; Hypertension; Sotalol | 1981 |
Sotalol, prolonged Q-Tc interval, and tachyarrhythmias.
Topics: Arrhythmias, Cardiac; Electrocardiography; Heart Ventricles; Humans; Sotalol | 1982 |
Identification of patients at high risk for sudden cardiac death.
Topics: Anilides; Arrhythmias, Cardiac; Death, Sudden; Encainide; Heart; Heart Ventricles; Humans; Prognosis | 1984 |
Sotalol-induced prolongation of the Q-T interval and attacks of unconsciousness.
Topics: Arrhythmias, Cardiac; Electrocardiography; Female; Heart Ventricles; Humans; Middle Aged; Quinidine; | 1984 |
Efficacy of intravenous sotalol on ventricular arrhythmias occurring during maximal exercise stress testing.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electroencephalography; Exerc | 1983 |
Replacement of amiodarone by sotalol for repetitive ventricular premature beats.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Female; Humans; Male; Middle Aged; Myocardial I | 1984 |
Electrophysiological effects of sotalol--just another beta blocker?
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Child; Electrocardiography; Female; Heart; Heart Cond | 1982 |
A case of sotalol poisoning.
Topics: Arrhythmias, Cardiac; Female; Humans; Middle Aged; Sotalol; Suicide, Attempted | 1982 |
[Study of the antiarrhythmic effects of Sotalol given orally].
Topics: Administration, Oral; Adolescent; Adult; Aged; Arrhythmias, Cardiac; Female; Humans; Male; Middle Ag | 1982 |
Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Electrocardiography; Female; Hemodynamics; Humans; Male; Mi | 1981 |
AVID necessity.
Topics: Amiodarone; Arrhythmias, Cardiac; Bias; Clinical Trials as Topic; Defibrillators, Implantable; Ethic | 1994 |
Efficacy and proarrhythmia of oral sotalol in pediatric patients.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Case-Control Studies; Child; Chi | 1995 |
Sotalol: what the emergency nurse needs to know.
Topics: Arrhythmias, Cardiac; Drug Interactions; Drug Monitoring; Emergency Nursing; Humans; Sotalol | 1995 |
Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide: implications for proarrhythmia due to triggered activity.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Cesium; Disopyramide; Dogs; Dose-Response Relation | 1993 |
Effects of flecainide and D-sotalol on myocardial conduction and refractoriness: relation to antiarrhythmic and proarrhythmic drug effects.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Electrocardiography; Electrophysiology; F | 1993 |
Proarrhythmic effects of DPI 201-106 elicited with programmed electrical stimulation: a comparison with sotalol.
Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulatio | 1993 |
AVID necessity.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Defibrillators, Implantable; Heart Ventric | 1993 |
Iontophoresis for modulation of cardiac drug delivery in dogs.
Topics: Animals; Arrhythmias, Cardiac; Coronary Circulation; Dogs; Drug Carriers; Drug Implants; Iontophores | 1995 |
Class III Antiarrhythmic Drugs: Potential Impact on Arrhythmia Therapy. Symposium proceedings. Nice, France, 17 June 1992.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Sotalol | 1993 |
[Sotalol].
Topics: Arrhythmias, Cardiac; Humans; Sotalol; Structure-Activity Relationship | 1994 |
Pro- and antiarrhythmic effects of d-sotalol and dl-sotalol in an isolated tissue model of ischemia and reperfusion.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Guinea Pigs; Heart Conduction System; In Vitro Tec | 1994 |
Sotalol: a unique class III antiarrhythmic agent.
Topics: Arrhythmias, Cardiac; Humans; Sotalol | 1994 |
Sotalol in Life-Threatening Ventricular Arrhythmias: A Unique Class III Antiarrhythmic. Symposium proceedings. Phoenix, Arizona, September 19-22, 1991.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Sotalol; Tachycardia, Ventricular | 1993 |
Arrhythmogenic actions of class III antiarrhythmic drugs in spontaneously beating rabbit sino-atrial node cells.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Comp | 1993 |
Sotalol hydrochloride (Betapace): a new antiarrhythmic drug.
Topics: Arrhythmias, Cardiac; Cardiac Output, Low; Humans; Sotalol | 1994 |
Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Dilated; Drug Combinati | 1994 |
Class III antiarrhythmic action: the way forward?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Sotalol | 1993 |
Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiac Pacing, Artifici | 1993 |
Clinical safety profile of sotalol in the treatment of arrhythmias.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Sotalol; Stroke Volume; | 1993 |
Effect of sotalol on heart rate variability assessed by Holter monitoring in patients with ventricular arrhythmias.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography, A | 1993 |
Sotalol for cardiac arrhythmias.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Humans; Sotalol; Tachycardia | 1993 |
Sotalol marketed for life-threatening arrhythmias.
Topics: Administration, Oral; Arrhythmias, Cardiac; Drug Approval; Humans; Sotalol; Tachycardia, Ventricular | 1993 |
Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs.
Topics: Amiodarone; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans | 1995 |
SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats.
Topics: Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans | 1995 |
The SWORD of Damocles.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Myocardial Infarction; Randomized | 1996 |
Discontinuation of Sotazide.
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Contraindications; Drug Combi | 1996 |
The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrophysiolog | 1996 |
From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduct | 1996 |
The in-vivo cardiovascular effects of a putative class III anti-arrhythmic drug, AM 92016.
Topics: Anesthesia, Inhalation; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Guine | 1996 |
Long-term results of electrophysiologically guided sotalol therapy for life-threatening ventricular arrhythmias.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Male; | 1996 |
Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel | 1996 |
Initial clinical experience with an implantable human atrial defibrillator.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Pacing, Arti | 1997 |
Effects of azimilide and d,l-sotalol on the heart rate and blood pressure response to isoproterenol in anesthetized rats.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; | 1997 |
Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Disease Models, Anima | 1997 |
Proarrhythmic effects of DL- and D-sotalol on the "border zone" between normal and ischemic regions of isolated ventricular myocardium and antiarrhythmic effects on reperfusion.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Guinea Pigs; Heart | 1998 |
Combination of sotalol and quinidine in a canine model of torsades de pointes: no increase in the QT-related proarrhythmic action of sotalol.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Drug Therapy, C | 1998 |
Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia | 1998 |
T wave alternans after sotalol: evidence for increased sensitivity to sotalol after conversion from atrial fibrillation to sinus rhythm.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atrial Fibrillation; Electrocardiography; Female; | 1998 |
Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Defibrillators, Implantable; Female; | 1999 |
[Role of electrophysiology in the prognosis and therapy of cardiomyopathies].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopath | 1999 |
Effects of the T-type Ca(2+) channel blocker mibefradil on repolarization of guinea pig, rabbit, dog, monkey, and human cardiac tissue.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; | 2000 |
Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit.
Topics: Adrenergic alpha-Agonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, An | 2000 |
The role of sarcoplasmic reticulum in the protective effect of class III drugs against Ca2+ overload.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bridged Bicyclo Compounds, Heterocyclic; Bucl | 1999 |
[Ion channels and arrhythmias].
Topics: Action Potentials; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atrial Fib | 2000 |
Modulation of arrhythmias by isoproterenol in a rabbit heart model of d-sotalol-induced long Q-T intervals.
Topics: Action Potentials; Analysis of Variance; Animals; Arrhythmias, Cardiac; Blood Pressure; Electrocardi | 2000 |
Gender and seasonally related differences in myocardial recovery and susceptibility to sotalol-induced arrhythmias in isolated rabbit hearts.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Disease Susceptibility; Electrocardiography; Elect | 2000 |
Antiarrhythmic and electrophysiological effects of GYKI-16638, a novel N-(phenoxyalkyl)-N-phenylalkylamine, in rabbits.
Topics: Action Potentials; Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models | 2000 |
Electropharmacological characterization of cardiac repolarization in German shepherd dogs with an inherited syndrome of sudden death: abnormal response to potassium channel blockers.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chromans; Death, Sudden, Cardiac; Dog Disease | 2000 |
The class III antiarrhythmic effect of sotalol exerts a reverse use-dependent positive inotropic effect in the intact canine heart.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Disease Models, Anima | 2000 |
Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation.
Topics: Acetylcholine; Action Potentials; Adenosine; Adrenergic beta-Antagonists; Animals; Arrhythmias, Card | 2000 |
Which beta-blocker?
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Bradycardia; Heart Failure; Huma | 2001 |
Effects of acute global low-flow ischemia on triggered arrhythmias in d-sotalol-induced long Q-T intervals in perfused rabbit hearts.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Electrocardiography; Female; Heart Condu | 2001 |
The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Topics: Action Potentials; Animals; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Cisapride; D | 2001 |
Sotalol in treatment of pediatric cardiac arrhythmias.
Topics: Adolescent; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Child; Child, Pre | 2001 |
Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Arrhythmias, Cardiac; Electrocardiography; El | 2002 |
Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Amiodarone; Animals; Anti-Arrhythmi | 2002 |
Cellular basis for complex T waves and arrhythmic activity following combined I(Kr) and I(Ks) block.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chromans; Dogs; Electrocar | 2001 |
Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Approval; Drugs, Generic; Heart Ventricles; Human | 2001 |
Toxicity of aerosol propellants in the respiratory and circulatory systems. VII. Influence of pulmonary emphysema and anesthesia in the rat.
Topics: Adrenergic beta-Antagonists; Aerosol Propellants; Aerosols; Anesthesia; Animals; Arrhythmias, Cardia | 1975 |
Sotalol intoxication, two patients with concentration-effect relationships.
Topics: Adult; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Electrocardiography; Half-Life; Human | 1979 |
Comparative study of propranolol, sotalol and INPEA in ouabain-induced cardiac arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Ethanolamines; Female; Guinea Pigs; Male; Ouabain; Propranolol; | 1977 |
Effects of sotalol in twenty patients with cardiac arrhythmias.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Humans; Inject | 1977 |
Influence of the adrenal medulla on cardiac rhythm disturbances following acute coronary artery occlusions.
Topics: Adrenal Medulla; Animals; Arrhythmias, Cardiac; Cats; Coronary Disease; Epinephrine; Female; Lidocai | 1975 |
[Special symposium: Improvement of Therapy of Cardiac Arrhythmias. Class III Antiarrhythmic Drugs Focussing on Sotalol and D-Sotalol. Nizza, 17-20 June 1992].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Sotalol | 1992 |
Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electrocardiography; Encainide; Hemodyn | 1992 |
Short- and long-term antiarrhythmic and hemodynamic effects of d,l-sotalol in patients with symptomatic ventricular arrhythmias.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Drug Evaluation; Electrocardiography, Ambulato | 1992 |
Promising news about antiarrhythmic drug therapy.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Sotalol | 1991 |
The management of cardiac arrhythmias: The role of encainide and sotalol. A symposium. March 24-25, 1988. Proceedings.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Humans; Sotalol | 1990 |
Serious interactions of sotalol with amiodarone and flecainide.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Drug Administration Schedule; Drug Interactions; Drug Therap | 1990 |
[Clinical matters of rhythm disturbances].
Topics: Arrhythmias, Cardiac; Humans; Sotalol | 1990 |
Concentration/response relations for the multiple antiarrhythmic actions of sotalol.
Topics: Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Electrocardiography; Heart Rate; Humans; Sot | 1990 |
Excretion of sotalol in breast milk.
Topics: Adult; Arrhythmias, Cardiac; Cardiomyopathies; Female; Humans; Infant, Newborn; Milk, Human; Pregnan | 1990 |
QT dispersion: an indication of arrhythmia risk in patients with long QT intervals.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Child; Electrocardiography; Female; Heart; Heart Rate; Huma | 1990 |
Delayed ventricular repolarization as an anti-arrhythmic principle.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bund | 1985 |
Experimental evidence for the antiarrhythmic action of indoramin.
Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Cats; Coronary Vessels; Electrocardiography; Guinea P | 1986 |
Long-term sotalol therapy in patients with ventricular arrhythmias.
Topics: Aged; Angina Pectoris; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiomyopathy, Dilated; | 1986 |
QT prolongation and arrhythmia suppression.
Topics: Acecainide; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Deafness; Death, Sudden; Elect | 1985 |
Control of cardiac arrhythmias by selective lengthening of repolarization: theoretic considerations and clinical observations.
Topics: Acecainide; Action Potentials; Amiodarone; Arrhythmias, Cardiac; Depression, Chemical; Electrocardio | 1985 |
[Therapeutic indications for sotalol 160 mg].
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiomyopathy, Dil | 1985 |
Variations of sotalol kinetics in renal insufficiency.
Topics: Arrhythmias, Cardiac; Creatinine; Half-Life; Humans; Kidney Diseases; Risk Factors; Sotalol | 1989 |
Effect of sotalol against reperfusion-induced arrhythmias in Sprague-Dawley and Wistar rats.
Topics: Animals; Arrhythmias, Cardiac; Electrophysiology; Hemodynamics; In Vitro Techniques; Male; Myocardia | 1989 |
Relation between ventricular function and antiarrhythmic responses to sotalol.
Topics: Adult; Aged; Arrhythmias, Cardiac; Electrocardiography; Electrocardiography, Ambulatory; Heart Condu | 1989 |
Pharmacologic properties of acebutolol: relationship of hydrophilicity to central nervous system penetration.
Topics: Acebutolol; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Blood-Brain Barrier; Cats; C | 1985 |
[Rational treatment of heart rhythm disorders. International symposium on "The Management of Cardiac Arrhythmias: the Role of Encainide and Sotalol". 24-25 March 1988, Wallingford (USA)].
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Humans; Sotalol | 1988 |
Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmias.
Topics: Administration, Oral; Arrhythmias, Cardiac; Drug Resistance; Electric Countershock; Electrophysiolog | 1989 |
[Proarrhythmic effect of ajmaline in idiopathic ventricular tachycardia].
Topics: Adult; Ajmaline; Arrhythmias, Cardiac; Electrocardiography; Female; Humans; Infusions, Intravenous; | 1989 |
Prevention of ventricular fibrillation by metoprolol in a pig model of acute myocardial ischaemia: absence of a major arrhythmogenic role for cyclic AMP.
Topics: Acute Disease; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Blood Pressure; Coronary Circu | 1986 |
Assessment of drug effects on spontaneous and induced ventricular arrhythmias in a 24-h canine infarction model.
Topics: Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Dogs; Electrocardiogr | 1987 |
[Ventricular tachyarrhythmia induced by low doses of sotalol: torsade de pointes or polymorphous ventricular tachycardia?].
Topics: Administration, Oral; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Dose-Response Relationship, | 1988 |
Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs.
Topics: Acetylcholine; Animals; Arrhythmias, Cardiac; Autonomic Nervous System; Dogs; Female; Heart Conducti | 1988 |
The effect of sotalol on exercise-induced ventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Cardiomyopathies; Coronary Disease; D | 1988 |
Comparative investigations on the antiarrhythmic and electrophysiologic effects of class I-IV antiarrhythmic agents following acute coronary artery occlusion.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Dogs; Female; Heart Conduct | 1987 |
Arrhythmogenesis--a European perspective.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Utilization; Europe; Humans; Mexileti | 1987 |
Concentration-dependent pharmacologic properties of sotalol.
Topics: Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Exercise Test; Humans; Kinetics; Placebos; S | 1986 |
[Therapy of drug-resistant ventricular arrhythmias].
Topics: Adult; Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Heart Ventricles; Humans; Male; Midd | 1986 |
Diseases and drugs causing prolongation of the QT interval.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Humans; Hypertension; Lon | 1987 |
Sotalol infusion in the treatment of supraventricular tachyarrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Female; Humans; Male; Middle | 1985 |
Effect of Sotalol on clinical arrhythmias.
Topics: Administration, Oral; Aged; Amino Alcohols; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutte | 1972 |
Early arrhythmias following experimental coronary occlusion in conscious dogs and their modification by beta-adrenoceptor blocking drugs.
Topics: Acetanilides; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Blood Pressure; Consciousn | 1973 |
Some cardiovascular effects of timolol a new beta-adrenergic blocking agent.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; | 1973 |
A study of the antiarrhythmic action of certain beta-blocking agents.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Cats; Depression, Chemical; Digoxin; Fem | 1974 |
Toxicity of aerosol propellants on the respiratory and circulatory systems. I. Cardiac arrhythmia in the mouse.
Topics: Aerosol Propellants; Aerosols; Animals; Arrhythmias, Cardiac; Atropine; Electrocardiography; Heart B | 1974 |
Effects of lidocaine, propranolol, and sotalol on ouabain-induced changes in transmembrane potential of canine Purkinje fibers.
Topics: Action Potentials; Amino Alcohols; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Digitalis | 1972 |